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ABSTRACT 
 
Introduction 
According to UNAIDS/WHO (2009), HIV/AIDS is a global problem that needs to 
be addressed. Universal access to antiretroviral therapy (ART) has been expanded 
significantly in both low and middle-income countries. To achieve the effectiveness of 
antiretroviral therapy, adherence to ART must be optimal (≥ 95%) and maintained for life. 
However, adherence to antiretroviral therapy is difficult to reach this optimal goal and 
faces many problems, especially in resource-poor settings. In 2007, Cambodia had 
approximately 75,000 adults and children living with HIV, including 0.8% of all adults 
aged from 15-49 years. The Ministry of Health of Cambodia through the National Center 
for HIV/AIDS, Dermatology, and STDs (NCHADS) has expanded ART program 
coverage substantially. The number of people living with HIV/AIDS patients on ART has 
increased by 40 percent, from 26,664 in 2007 to 37,315 in 2009. Also, the number of 
HIV/AIDS patients on ART at Sihanouk Hospital Center of HOPE has increased to 2467 
by March 30, 2010. Since the number of HIV/AIDS patients on ART has increased 
dramatically, ART adherence of patients must be good in order to achieve effectiveness of 
the treatment. The objectives of this study were to discover barriers to adherence to 
antiretroviral therapy of HIV/AIDS patients at Sihanouk Hospital Center of HOPE. 
Methods 
The study was conducted at Sihanouk Hospital Center of HOPE between August 
16, 2010 and September 30, 2010. The study design was cross-sectional in the form of a 
xvii 
 
case-control study of poor ART adherent and good ART adherent patients, which 
employed both qualitative and quantitative approaches. Purposive and simple random 
sampling techniques were used in the study for recruiting poor ART adherent patients and 
good ART adherent patients respectively. Of 117 subjects selected for the study sample, 
60 were poor ART adherent patients, while 57 were good ART adherent patients. Primary 
data were collected using face-to-face interviews through the author-administered and 
structured questionnaire. Secondary data were collected using cohort data in order to 
identify poor ART adherent patients and good ART adherent patients among all 
HIV/AIDS patients who were receiving highly active antiretroviral therapy (HARRT) 
through the Visual Analogue Scale (VAS) at the Infectious Disease Department of 
Sihanouk Hospital Center of HOPE. Moreover, the secondary data were collected through 
a variety of other sources in a bid to find out relevant documents, information, and 
previous research findings. Data were coded and analyzed using SPSS version 18, and a 
Chi-square test was used to identify an association between dependent and independent 
categorical variables. 
Results 
Results of data analysis show that the majority (93%) of the total 117 research 
respondents are good ART adherent patients, while seven percent are poor ART adherent 
patients. The reasons for missing ART doses cited by research respondents were 
forgetfulness (22.2%), being busy, conflicts with family and neighbors, lack of time 
reminders such as alarm clocks and cell phones, altogether 35.9%, being too ill (6%), fear 
of stigma/disclosure (6%), drunk with alcohol (5.1%), feeling better (2.6%), developed 
xviii 
 
toxicity/side effects (2.6%), too many pills/pill burden (2.6%), and stock was finished 
(1.7%). Univariate data analysis shows that ART side effects were statistically 
significantly associated with poor ART adherence (X²=7.150, df =1, P-value=0.007). 
Types of ART regimens, co-opportunistic infection drug treatments, knowledge of ART, 
educational levels, patient’s location of residence, and poverty status were not 
significantly associated with poor ART adherence. Other factors such as gender, age 
groups, CD4 groups, WHO stages, marital status, occupations, and food status were not 
significant predictors for poor ART adherence.  
Conclusions 
It was concluded that most of the research respondents (93%) were good ART 
adherent patients, while seven percent were poor ART adherent patients. The factors for 
poor ART adherence cited by research respondents were forgetfulness, being busy, lack of 
time reminders, being too ill, fear of stigma/disclosure, drunk with alcohol, feeling better, 
side effects, and the pill burden. ART side effects were significantly associated with poor 
ART adherence, while ART drug regimens, co-infection drug treatments, HIV/AIDS 
disease factors, and socio-demographic and economic factors were not significantly 
associated with poor ART adherence. 
Based on the findings above, in order to enhance ART adherence, the Cambodian 
government and other stakeholders could take stronger measures to reduce and manage 
ART side effects by providing education and training to clinicians, counselors, nurses, and 
pharmacists. Furthermore, the government, through the Ministry of Health, could intensify 
health education campaigns against stigma and discrimination and promote family and 
xix 
 
community support for HIV/AIDS patients, and provide patients with time reminders such 
as alarm clocks. The findings of this study could be an important resource for ART 
program managers and policy makers attempting to achieve the success of antiretroviral 
therapy. 
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CHAPTER I: INTRODUCTION 
1.1. Rationale of the study 
1.1.1. Background  
 This section provides detailed situation of HIV/AIDS in general and situation 
of HIV/AIDS in Cambodia. 
 1.1.1.1. Situation of HIV/AIDS in general 
Human Immunodeficiency Virus (HIV) is a virus that can enter the human 
body by different modes of transmissions such as sexual intercourses, intravenous 
drug injections, blood transfusion, needle and syringe injuries, breast-feeding, and 
mother-to-child transmissions. When an HIV is inside the human body, it multiplies 
rapidly, attacks and kills immunity-system-protecting-lymphocytic T cells such as 
macrophages and especially CD4; later on, the numbers of CD4 will decrease 
substantially. People infected with HIV can develop Acquired Immune Deficiency 
Syndrome (AIDS), a condition in which their immune system begins to fail, leading 
to life threatening opportunistic infections such as respiratory diseases, skin diseases, 
sexually transmitted diseases, gastro-intestinal diseases (specifically diarrhea), 
lymphatic system diseases, tuberculosis, and nervous system diseases such as 
meningitis. 
HIV/AIDS is one of the most serious diseases that cannot be cured and it 
causes many problems to people living all over the world, especially in the 
developing countries, of Sub-Saharan Africa, South and South-East Asia. HIV/AIDS 
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produces serious and negative socio-economic impacts on individuals, households, 
communities, and nations. When one HIV-infected person becomes an AIDS patient, 
he or she suffers from a lack of immunity and poor quality of life. As a result, he or 
she cannot study, work, or earn enough money to support himself or herself, let alone 
his or her family. Moreover, he or she cannot participate in other socio-economic 
activities in the community as well as the country and finally he or she encounters 
poverty. In addition, if one country has many HIV/AIDS patients, it faces a shortage 
of human resources because of the high morbidity and mortality of the patients and 
the country needs to spend a large amount of money on HIV/AIDS patients’ 
prevention, treatment, care, support, and other related management. Therefore, the 
country may be unable to build and develop the nation. Hence, poverty ensues. HIV 
infections have spread from one country to another and from one continent to another 
to create a world pandemic. 
Since the beginning of the epidemic, almost 60 million people have been 
infected with HIV and 25 million people have died of HIV/AIDS-related causes. In 
2008, about 33.4 million people were living with HIV/AIDS (PLWHA) and 2.7 
million new infections occurred. The number of these new infections was 
approximately 30 percent lower than the number for 1996, which appears to be a peak 
year for such infections. There was also a significant decrease in the number of AIDS 
related deaths, from 3.5 million in 1996 to 2.1 million in 2008 [Joint United Nations 
Program on HIV/AIDS (UNAIDS)/ World Health Organization (WHO), 2009)]. The 
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estimated worldwide adult (15-49) HIV prevalence was around 0.9%. Of the total 
33.4 million PLWHA, adults and children less than 15 years account for 31.3 million 
and 2.1 million respectively. 15.7 million out of the 31.3 million adult HIV patients 
were women. In the same year, 2008, the number of HIV infected children globally 
was 2.7 million and young people accounted for approximately 40 percent of all new 
adult (older than 15) HIV infections. In Sub-Saharan Africa, PLWHA accounted for 
67 percent of the total HIV infected patients and 91 percent of all new infections 
among children in the world (UNAIDS/WHO, 2009). Worldwide, the HIV epidemic 
is mainly caused by heterosexual intercourse, which accounts for greater than 75 
percent (Matte, Lajoie, Lacaille, Zijenah, Ward, & Roger, 2004). The second mode of 
HIV transmission is homosexual intercourse (Volk et al., 2006) and the third 
mode/route of transmission is through unsafe drug injections amongs drug users 
which varies from country to country (Hope et al., 2005). 
The level of HIV prevention in the world is still limited. In 2008, the 
percentage of pregnant women infected with HIV receiving antiretroviral therapy for 
prevention of mother to child transmission of HIV (PMTCT) increased from 33% in 
2007 to 45% in 2008. However, less than 40% of young people had basic information 
on HIV and the same percentage of people living with HIV/AIDS know their HIV 
status (UNAIDS/WHO, 2009). Though there are international campaigns for HIV 
prevention, care, treatment, and support, the number of new infections still exceeds 
the number of HIV/AIDS patients on Antiretroviral Therapy (ART). For every two 
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people starting treatment, a further five become infected with the virus, because while 
on antiretroviral medications, the quality of life of patients receiving treatment 
improves and thus they transmit the disease to others (UNAIDS/WHO, 2009). 
Globally, the number of people living with HIV/AIDS in need of ART is 
approximately 9.5 million. However, only close to four million patients have received 
ART, which accounts for 42% coverage of adult patients and 38% of children in low 
and middle-income countries, which still remains low compared with the number of 
patients who require ART (UNAIDS/WHO, 2009).  
Having access to ART has a significant impact on HIV related deaths. For 
example, a multicenter study of 12 high-income countries indicates that the excess 
rate of mortality among PLWHA, compared with the HIV uninfected population, 
dropped by 85 percent owing to the introduction of highly active antiretroviral 
therapy (HAART) (Bhaskaran et al., 2008). However, the decline in AIDS related 
deaths due to successful ART contributed to an increase in HIV prevalence in high-
income countries (Center of Disease Control and Prevention, 2008). Moreover, 
HAART has increased the survival of PLWHA in low and middle-income countries. 
For instance, a study in Sao Paulo, Brazil shows that average survival increased from 
four months in 1991-1995 to 50 months in 1998-2001 (Kilsztajn, Lopes, Do Carmo, 
& Rocha, 2007). In the same year, 2008, the number of people living with HIV/AIDS 
in Sub-Saharan Africa was 22.4 million, equaled 5.2% adult HIV prevalence rate; 
new HIV infections, AIDS related deaths, and AIDS orphans were 1.9, 1.4, and 14 
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million respectively. In addition, among 6.7 million people in need of ART, only 2.9 
million have received ART, which accounted for 44% of ART coverage of 
HIV/AIDS patients in the region (UNAIDS/WHO, 2009).  
Since the epidemic started, the disease has continued to ravage families, 
communities, and countries throughout the world. Consequently, many people 
infected with HIV/AIDS were unable to work, make their living and engage in other 
activities; eventually they have died. In response to this shocking situation, the 
international communities, local organizations, civil societies, and the governments 
have taken serious actions in fighting together against the outbreak of the HIV/AIDS 
disease. These measures include Voluntary Confidential Counseling and Testing 
(VCCT) of HIV, HIV preventions, home-based care, opportunistic infection 
treatments, antiretroviral therapy, and other related managements. 
With the strong effort and struggle of local and international communities in 
response to the HIV/AIDS epidemic and the enormous number of deaths of AIDS 
patients, the number of people living with HIV/AIDS worldwide had declined to 33.4 
million by 2008. Of these, 22.4 million were in Sub-Saharan Africa and 4.7 million in 
Asia, of which 3.8 million PLWHA were in South and South-East Asia 
(UNAIDS/WHO, 2009). 
According to UNAIDS/WHO (2009), the number of people living with 
HIV/AIDS in Asia in 2008 was 4.7 million. There were 350,000 new adult infections 
and 21,000 new children infections and there were 330,000 AIDS related deaths. The 
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estimated regional adult (15-49) HIV prevalence was about 0.3%. The HIV annual 
incidence has dropped by more than half; the regional epidemic peaked in the mid-
1990s and has remained nearly stable since 2000. Even though the annual number of 
deaths related to AIDS in South and South-East Asia in 2008 was about 12 percent 
lower than the number of AIDS deaths in 2004, the AIDS-related mortality rate in 
Asia continues to rise, with the number of deaths in 2008 more than three times 
higher than that in 2000. 
The epidemic patterns of HIV infections in the region have a wide variation. 
In fact, Asian population is very diversified and large, which represents about 60 
percent of the world population. The number of people living with HIV/AIDS in Asia 
is high, second only to Sub-Saharan Africa, in comparison with worldwide PLWHA. 
India contains about half of Asia’s HIV prevalence. Moreover, all countries in Asia, 
except for Thailand, had HIV prevalence less than 1 %. Due to the large population in 
the region, although Asia’s HIV prevalence is low, the number of HIV patients still 
contributes to a large proportion of the HIV burden on the globe (UNAIDS/WHO, 
2009). As of 2007 in China, the number of PLWHA was 700,000, new infections 
50,000 and AIDS related deaths 20,000 (Wang et al, 2009). Furthermore, epidemic of 
HIV in Asia has been mainly focused on the most-at-risk population of HIV 
infections such as injecting drug users, sex workers as well as their clients, and Men 
who have sex with Men (MSM). In general, injecting drugs and sexual contact, 
especially heterosexual contact, are still the primary modes of HIV transmission in 
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China and Asia (Wang et al., 2009). In the Asian region, injecting drug users are 
among people who have the highest HIV prevalence, which accounted for about 16%. 
However, the HIV prevalence of this high-risk population varies substantially from 
one country to another country (Mathers et al., 2008). 
Even though the estimated annual number of new HIV infections in South and 
South-East Asia declined from 450,000 in 2001 to 340,000 in 2007, most South-East 
Asian countries, especially Indonesia, had an increase in HIV prevalence. The 
increasing number of new infections made Indonesia the site of the fastest growing 
epidemic in Asia despite the fact that the national HIV prevalence was low, 0.16 
percent; and the total number of people living with HIV/AIDS was 193,000 as of 
2006 (World Health Organization, 2007). Moreover, the primary modes of HIV 
transmission in Indonesia were injecting drug use, unprotected paid sex, and 
unprotected sex between men (Ministry of Health of Indonesia, 2006). In Thailand, in 
2004, the number of people living with HIV/AIDS was 572,500, new HIV infections 
19,500, and projected new AIDS cases 49,500. Sexual contact, especially 
heterosexual, has remained the primary mode of HIV transmission in Thailand 
(Rueankham, 2008). The number of people living with HIV/AIDS in Vietnam in 
2007 was estimated to be 293,000, which equaled 0.53 % prevalence in the general 
population. It was estimated that 28.4% of PLWHA were on ART in 2007. HIV 
infections in Vietnam are primarily among the most-at-risk populations such as 
injecting drug users, female sex workers, and men who have sex with men (MSM) 
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(National consensus workshop on United Nations General Assembly Special Session 
on HIV/AIDS, 2008). In Lao’s People Democratic Republic in 2009, people living 
with HIV/AIDS accounted for 8,000, which equaled 0.2 % prevalence rate among 15-
49 years old population. Since 2006, the ART coverage of HIV/AIDS patients in this 
country has increased to 92%. The major modes of HIV transmission in this country 
(87%) were due to heterosexual contact, followed by unknown sources 6.5%, and 
mother-to-child transmission 4.6% (National Committee on the Control of AIDS, 
2010). 
Despite low HIV prevalence, the economic impact and consequences of 
HIV/AIDS will put an additional six million households in Asia into poverty by 2015 
if national and regional responses are not made and strengthened significantly and 
effectively (Commission on AIDS in Asia, 2008). 38% of all HIV/AIDS patients in 
need of ARVs in Asia were receiving ART, just below the global coverage (42%) in 
low and middle-income countries by the end of 2008, which represents a seven-time 
increase in ART access over five years (UNAIDS/WHO, 2009). Though Asia has 
made much progress in HIV prevention and ARV treatment, many countries cannot 
afford to provide enough priority to HIV prevention. Prevention of high-risk 
behaviors is still a concern (National AIDS commission, 2006-2007). 
1.1.1.2. Situation of HIV/AIDS in Cambodia 
Cambodia has been the victims of a civil war, which lasted over 30 years. The 
wars, especially the one that occurred during the Pol Pot (Khmer Rouge) regime, 
9 
 
destroyed almost all the infrastructure, human as well as natural resources, properties, 
other valuable belongings, and particularly the health care system. The health care 
system of Cambodia, the worst in Asia, was completely demolished such as hospital 
amenities, equipments, medical supply, and health care personnel. After the Pol Pot 
regime ended in 1979, few health care providers had survived; there were 45 medical 
doctors (however, 20 of them left the country), 26 pharmacists, 28 dentists, and 728 
medical students (Laura & McGrew, 1990). As a result, Cambodia has become the 
poorest country in the South East Asia region. Cambodia’s Gross Domestic Product 
(GDP) per capita was US$ 610 (1US$=4000 Riel, local currency) and 30.1 percent of 
the total population, 14,805,358 millions, were living below the poverty line, earning 
less than 1US$ per day (World Bank, 2009).  
In 2008, life expectancy of Cambodian people at birth was 59 years for men 
and 65 years for women; neonatal mortality rate per 1,000 live births was 48; infant 
and under 5 mortality rate per 1,000 live births was 71 for males and 58 for females 
and 89 for male and 75 for female respectively. Adult mortality rate per 1,000 
population was 371 for male and 301 for female; and maternal mortality ratio per 
100,000 live births was 540 (WHO, 2008). 
The educational level of Cambodian people is still limited. In 2007, the adult 
literacy rate was about 75 percent, women and men accounted for 66 and 85 percent 
respectively. Generally, people living in the capital city, Phnom Penh, have higher 
education than those living in other urban and rural areas. Moreover, men have a 
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higher educational level than that of women in both urban and rural areas (National 
Institute of Statistics Ministry of Planning, 2007). 
 
Source: Cambodia socio- economic survey, 2007. National Institute of Statistics, 
Ministry of Planning 
Among people aged 25 years and over, 37 percent of women and 15 percent 
of men had no education or had not finished first grade. The number of women and 
men who did not complete primary school was similar. In particular, the higher the 
level of a school, the lower the number of women enrolled (National Institute of 
Statistics Ministry of Planning, 2007).  
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Source: Cambodian Socio-Economic Survey, 2007. National Institute of 
Statistics, Ministry of Planning 
Such low educational attainments are most likely to make people more 
vulnerable to diseases since education and health conditions have links to each other. 
There is a negative association between lower educational level and HIV infections; 
this means that when people have lower educational background, they are more likely 
to have HIV infections ( Piot, Bartos, Ghys, Walker, & Schwartländer, 2001). 
According to the National Center for HIV/AIDS, Dermatology, and STDs 
(NCHADS) (2000), the first HIV infection was reported to the National Blood 
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Transfusion Center in Phnom Penh in 1991. Later, the first case of AIDS was 
detected and reported to the Ministry of Health of Cambodia in 1993. 
 
 
 
        
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
UNAIDS/WHO (2007) and National Center for HIV/AIDS, Dermatology, and 
STDs (NCHADS)’s estimates (2008) showed that Cambodia had one of the most 
serious HIV epidemics with 0.8 percent HIV prevalence, second only to Thailand, 
with 1.4 percent HIV prevalence among Southeast Asian countries. There were 
approximately 75,000 adults and children with HIV in 2007, about 0.8% of adults 
aged from 15-49 years old had HIV infection, and the number of AIDS related deaths 
was 6,900 (NCHADS, 2008). Even though the prevalence of HIV in Cambodia had 
dropped from the peak 3.0% in 1997 to 1.9% in 2003 and 0.8% in 2007 (NCHADS, 
2008), these figures cannot completely mean that new infections are decreasing as the 
drop in prevalence may result from the deaths of long-term AIDS cases and it is still 
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the second highest in the region. It is estimated that the HIV prevalence will continue 
to decline from the current level (0.8%) before 2011 if the interventions are sustained. 
A resurgence of the HIV epidemic, however, cannot be ruled out because of the risk 
of second wave of new infections among most-at-risk populations such as female 
direct and indirect sex workers, their clients and other sexual partners, men who have 
sex with men (MSM) and injecting drug users (IDUs) (National AIDS Authoriy, 
2008). 
National response to HIV epidemic has increased remarkably, which is the 
achievement of cooperation and coordination between the government and civil 
society, including local non-governmental organizations, international non-
governmental organizations, UNAIDS, WHO, United Nations Children’s Fund 
(UNICEF), and United States Agency for International Development (USAID). 
Moreover, NCHADS plays a leading role in fulfilling the national response in order 
to reverse the HIV epidemic. HIV prevention interventions among general 
populations in the country have increased significantly, especially those in target 
groups. For example, the number of sites for prevention of mother-to-child 
transmission of HIV (PMTCT) have expanded from 27 sites in 16 operational 
districts in 2005 to 98 sites in 58 operational districts in 2007 and to 200 sites in 67 
operational districts in 2009 (National AIDS Authority, 2010). By 2009, 32.3 percent 
of the total 2475 HIV-infected pregnant women received ART in order to prevent 
transmission from mother to child, which increased from 1.2 percent in 2003 to 11.2 
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percent in 2007 (National AIDS Authority, 2010). Furthermore, health facilities that 
provide voluntary confidential counseling and testing (VCCT) have been increasing 
rapidly from 197 in 2007 to 233 in 2009 (National AIDS Authority, 2010). The 
number of people tested for HIV has risen dramatically from 212,789 in 2006 to 
363,799 in 2009 (NCHADS, 2010). However, there has been no new available data 
on voluntary confidential counseling and testing (VCCT) among the general 
population, female sex workers and MSM or prevention programs for most at risk 
populations (National Institute of Statistics Ministry of Planning, 2008).  
In order to achieve the universal access target, the Ministry of Health of 
Cambodia through NCHADS and civil society have worked together to expand the 
coverage of care, ARV treatment, and support services in 20 out of the 24 provinces 
of Cambodia. As a result, health facilities with ART services have increased 
substantially from 30 sites in 2005 to 52 sites in 2009 (National AIDS Authority, 
2010). The number of people living with HIV/AIDS (PLWHA) in need of ART was 
30,200 in 2009 and increased to 31,600 by 2010 (National AIDS Authority, 2008). 
Remarkably, the number of AIDS related deaths declined sharply from 9950 in 2006 
to 1210 in 2009 owing to the impact of ART. This indicates that ART program had 
averted 8,740 deaths in the three-year period (NCHADS, 2007). ART program has 
scaled up significantly because the number of HIV/AIDS patients in need of ART, as 
well as, those on ART is increasing and the advantages of ART are well 
demonstrated. To achieve ART success, HIV/AIDS patients must have optimal/good 
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adherence (adherence equal to or greater than 95%) to ART. Good adherence is the 
key to the effectiveness of ART (Malangu, 2008), while sub-optimal/poor adherence 
(adherence less than 95%) is the main predictor of HIV drug resistance, ART failure, 
and patient’s survival (Cauldbeck et al., 2009).   
About 5% of PLWHA were on second-line ART and the resources required 
for total ART were US$ 4,142,800 (National AIDS Authority, 2008). Of this amount, 
US$ 1,409,360 was for second-line adult ART in 2009 and the resources required for 
2010 increased up to US$ 4,336,800; from which US$ 1,409,360 was for second-line 
adult ART (National AIDS Authority, 2008). In addition, the costs of second-line 
ART are US$ 892/month which is about 10 times more expensive than those of first-
line ART (US$ 92/month) (Discussion on first-line regimens and second-line 
regimens, 2008).  
In Cambodia, overall adherence level is estimated to be 87% (National AIDS 
Authority, 2007). Another study on simplified assessment of antiretroviral adherence 
and prediction of virological efficacy in HIV-infected patients in Calmette hospital, 
Phnom Penh, Cambodia 2003 (Olivier et al., 2010) showed that the adherence level 
assessed by the Visual Analog Scale (VAS) method was 71%. 
The HIV/AIDS Department of Sihanouk Hospital Center of HOPE (SHCH) is 
a private non-governmental organization, established in 1997 after an HIV/AIDS 
epidemic occurred in Phnom Penh, the Capital city of Cambodia. It provides health 
care services free of charge. Since 1997, the Department has been recognized as an 
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HIV/AIDS Center for treatment and training in terms of supporting the HIV/AIDS 
National program that consists of 52 health facilities with ART services for the entire 
country. Furthermore, Sihanouk Hospital Center of HOPE has been known for its 
better quality of management and care of HIV/AIDS but that level is not high enough 
to meet the needs of people living with HIV/AIDS. By March 2010, there were 2,467 
PLWHA on ART; of these 2,373 (95%) were on first-line ART, while 94 (4%) were 
on second-line ART (Sopheak, 2010). Of the 2467 HIV/AIDS patients, 2426 VAS 
were done, within which, 75 (3%) patients had poor adherence (adherence< 95%) 
(Sopheak, 2010). VAS is one of the tools used to measure the patient’s self-reported 
adherence to ART in the last month before it is done. For example, with an ART 
regimen which is taken twice daily, if a patient misses less than or equal to three 
doses per month means good adherence (adherence level ≥ 95%) while missing at 
least four doses per month means poor adherence (adherence level< 95%) (Soklida, 
2101).  
1.1.2. Literature review and problem statement 
1.1.2.1. Overview 
HIV/AIDS disease is not curable, however, it can be treated by Antiretroviral 
Therapy (ART) to prolong survival and improve the quality of life of patients. 
However, it requires adherence to a quite difficult regime of drugs for a lifetime. 
Adherence to ART is defined as sticking to the treatment plan by taking the correct 
dose of drugs at the correct time and in the correct way and follows dietary 
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restrictions and instructions such as food and fluid. It also means looking after drugs 
to make sure they are safe and effective to use (Castro, 2005). Another definition is 
that adherence to ART means taking the correct dose of medications, on schedule, 
and following dietary instructions (Maria, 2008). In general, these two definitions are 
used worldwide to define adherence to antiretroviral therapy. The former definition, 
on a broad perspective, sounds more precise than the latter one. One of the factors 
that contributes to successful treatment is that ART adherence level is optimal (≥ 
95%), which means that there is no more than three doses missed per month for a 
twice-time-daily regime (Keith, 2007). A rise in any levels of adherence to ART is 
associated with a decrease in disease progression. For example, a 10 % increase in the 
level of adherence to ART causes a 21% drop in disease progression (Nischal, 
Khopkar, & Saple, 2005). However, poor adherence is linked to the development of 
drug resistance, lower rate of increase in CD4 cell counts, undetectable viral load, 
therapeutic success, and increased hospital days, higher mortality rate, and leads to 
poor overall outcomes (Hogan & Salomon, 2005).  
Non-adherence has been a global concern in many diseases, especially chronic 
ones. Adherence in chronic diseases is about 50 percent in developed countries; 
however, it is even lower in developing countries (World Health Organization, 2003). 
Similarly, adherence to antiretroviral therapy (ART) varies from 37 to 83 percent 
depending on drugs under study (Steel, Nwokike & Joshi, 2007). In addition, 
adherence levels vary from one study to another; more than 10 percent of patients 
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report missing at least one medication dose per day, while more than 33 percent 
report missing doses in the past two to four weeks (Chesney, 2000). Moreover, it is 
estimated that patients have taken their prescribed drugs about 50 percent incorrectly 
(Paterson et al., 2002). 
Good adherence to ART in resource-poor settings is certainly achievable, but 
in some countries, it is difficult to verify it based on the follow-up data of the 
patients’ compliance with treatment, which may not be available. Hence, it is hard to 
ascertain discontinuation of treatment, losses to follow-up and mortality (Hardon, et 
al., 2007).  
1.1.2.2. Conceptual framework 
Based on reviews of previous research, a conceptual framework was created. 
The diagram below demonstrates that people living with HIV/AIDS need to take 
antiretroviral drugs in order to survive and improve their quality of life. It also shows 
the outcomes of ART from both good adherence and poor adherence. Finally, the 
diagram indicates a variety of factors/barriers that can lead to poor adherence to 
antiretroviral therapy. This study focuses on identifying barriers to antiretroviral 
therapy adherence of the HIV/AIDS patients at Sihanouk Hospital Center of HOPE, 
Phnom Penh, Cambodia. The conceptual framework is divided into four main parts as 
follows: Antiretroviral therapy (ART), impacts of ART regimens on adherence, 
impacts of adherence on ART, and predictors of ART adherence. 
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Figure 1.4: Conceptual framework 
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1.1.2.2.1. Antiretroviral therapy  
Human Immuno-deficiency Virus (HIV) is a virus that enters the human body 
through a variety of modes of transmission such as sexual contact, injecting drug use, 
mother-to-child transmission, contaminated syringe and needle injury, and blood 
transfusion (Kenya National AIDS Control Council, 2009). While in human blood, 
HIV affects white blood cells, especially CD4 cells that protect and make the immune 
system strong. While HIV is in CD4 cells, it produces new copies, multiplies its 
numbers rapidly, and kills a number of CD4 cells. The immune system of HIV/AIDS 
patients, in fact, becomes weaker as CD4 cells decrease. Antiretroviral therapy is a 
treatment of choice for HIV/AIDS. It cannot cure this disease; however, it can 
prolong life and stop patients from being ill for many years. In reality, antiretroviral 
therapy plays a key role in slowing and reducing HIV reproduction and replication in 
blood (National Center for HIV/AIDS and STD Control Nepal, 2009). In order to be 
effective, ART requires HIV/AIDS patients to take at least three antiretroviral drugs 
together every day for a lifetime. Highly active antiretroviral therapy (HAART) is a 
treatment, which combines three or more ARVs. The general ART guideline 
recommends patients to take at least three drugs, except for the purpose of prevention 
of mother-to-child transmission; otherwise ART works for a short time, then it will 
not work, and finally the development of HIV drug resistance can occur (National 
Center of HIV/AIDS and STD Control Nepal, 2009). Antiretroviral drugs are 
classified, depending on which part of HIV replication they act on, into the following 
groups (World Health Organization, 2010). 
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 Nucleoside reverse transcriptase inhibitors (NRTI) 
 Non-nucleoside reverse transcriptase inhibitor (NNRTI) 
 Protease inhibitors (PI) 
The overall goals of antiretroviral therapy are to improve quality of life of 
patients by restoring immune system function, reducing morbidity and mortality 
related to HIV/AIDS, and suppressing maximal and durable viral load. Also, the 
goals are to reduce and prevent ongoing HIV transmission (National AIDS and STI 
control programme, Ministry of Health, 2005). 
1.1.2.2.2. Impact of ARV regimens on ART adherence  
Almost all HIV/AIDS patients on ART need to take a regimen of three or 
more ARVs to achieve treatment success (Grierson, Bartos, de Visser & McDonald, 
2000). Generally, the patient’s adherence to ART seems to decline over time while on 
a regimen with a high pill burden, frequent dosing, frequency and severity of side 
effects, and complexity of drug regimens (Nakiyemba, Aurugai, Kwasa, & Oyabba, 
2005). Moreover, fear and the presence of side effects also influence poor adherence 
(Nakiyemba, 1998). For example, metabolic reasons and gastro-intestinal symptoms 
account for 66 and 50 percent, respectively, influencing non-adherence (Cauldbeck et 
al., 2009). Dietary restriction of food and liquid is one of the main factors associated 
with poor adherence. It is known that some ARVs need to be taken on an empty 
stomach and others need to be taken after meals to adjust their ART time schedule 
making it hard for them to overcome drug intolerance (Nakiyemba, 1998). Some 
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ARVs have particular physical aspects and characteristics such as bigger tablet size as 
well as form and bitter taste, which discourage patients from taking their ARVs 
(Nakiyemba, Aurugai, Kwasa, & Oyabba, 2005).  
1.1.2.2.3. Impacts of adherence on ART 
While patients are on ART, two forms of adherence can occur: good 
adherence and poor adherence. 
1.1.2.2.3.1. Good adherence 
Good adherence to antiretroviral therapy provides optimal benefits such as 
maximum and durable viral suppression, increase in CD4, prevention of HIV drug 
resistance, promotion of immune recovery, decrease in morbidity and mortality, 
slowed disease progression, and thus, ART success (Steel, Nwokike, & Joshi, 2007). 
For example, one cohort study found that a mean increase in CD4 count of 83 and six 
cells/µL was associated with levels of adherence greater than 95 and less than 95 
percent, respectively (Mannheimer, Friedland, Matts, Child, & Chesney, 2002). 
Another study on ART adherence of 76 HIV-infected patients showed that no patients 
with a level of adherence greater than 90% progressed to AIDS, compared with 8% of 
those whose level of adherence was 51-90% and 41% of those with a level of 
adherence less than 50% (García de Olalla, Knobel, Carmona, Guelar, López-
Colomés, & Caylà, 2002). When ART success is achieved, the quality of life of 
HIV/AIDS patients is significantly improved and the expenses of HIV/AIDS related 
disease and other involved managements are even lower. In fact, the success of 
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antiretroviral therapy can reduce the expenditure and most importantly, it can 
contribute to the country’s development. 
1.1.2.2.3.2. Poor adherence 
Unlike good adherence, poor adherence to ART in low- and middle-income 
countries is the most serious problem preventing the success of treatment (Markos, 
Worku, & Davey, 2008). Poor adherence leads to HIV drug resistance, antiretroviral 
therapy failure, high morbidity and mortality rate, increase in hospital stays as well as 
other HIV/AIDS related disease management practices, high expenditures, and even 
higher rates of poverty (Markos, Worku, & Davey, 2008). For instance, the cost of 
first line-ART adults is US$ 92 per person per month, while the cost of second-line 
ART adults is US$ 892, which is nearly ten times more expensive (National AIDS 
Authority, 2008). Furthermore, in 2007 the number of HIV/AIDS patients on second-
line ART, which is used after first-line ART fails, in Cambodia was about five 
percent, however, it may increase in the following years due to the fact that more 
HIV/AIDS patients are currently on ART, and the number will also increase in the 
future (National AIDS Authority, 2008). Similarly, patients on second-line ART at 
Sihanouk Hospital Center of HOPE in 2010 were approximately 4 percent (Sopheak, 
2010). 
1.1.2.2.4. Predictors of adherence 
According to literature reviews, there are many factors influencing adherence 
to ART. However, they belong to five main categories: treatment regimens, patient 
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factors, disease characteristics, clinical settings, and social factors such as family and 
community support, stigma and discrimination (Machtinger & Bangsberg, 2006).  
1.1.2.2.4.1. Predictors related to treatment regimens 
As mentioned previously, the complexity of drug regimens, frequent dosing, 
liquid and food restrictions, high pill burdens, and side effects are the key elements 
that lead to non-adherence. A study on antiretroviral therapy in Brazil found that 
prevalence of adherence was 75 percent; the study shows that more complex regimen 
of ART and high pill burdens were the main causes of poor adherence (Nemes, 
Carvalho, & Souza, 2004). Another study in Botswana revealed that prevalence was 
77 percent. The factors that influenced non-adherence were side effects, complicated 
regimens, and the taste, size, frequent dosing, and high pill burdens, which included 
co-opportunistic infections drug treatment (Castro, 2005). Also, non-adherence was 
found to be associated with side effects in several studies as follows: The AIDS 
clinical trial group of 370 participants revealed that side effects were the strongest 
predictor of poor adherence (Ickovics & Meade, 2002). Another study in Ethiopia 
found that reporting symptoms and side effects in the last month before visits were 
associated with non-adherence (Markos, Worku, & Davey, 2008); another study in 
Bangalore, India showed that metabolic reasons and gastro-intestinal symptoms 
accounted for 66 and 50 percent, respectively, and were the main predictors of poor 
adherence to antiretroviral therapy; however, ART regimens were not statistically 
significantly associated with adherence (Cauldbeck, et al., 2009). ART pill burdens 
25 
 
including OI drugs were not significantly associated with poor adherence (Markos, 
Worku, & Davey, 2008; Zungu, 2009; Cauldbeck et al., 2009). 
1.1.2.2.4.2. Predictors related to patient factors 
Socio-demographic and economic factors of HIV/AIDS patients such as 
gender, age, marital status, occupation, education, poverty, food, knowledge and 
attitude about antiretroviral therapy, housing, and psychological problems are 
associated with poor adherence (Nemes, Carvalho & Souza, 2004; Machtinger & 
Bangsberg, 2006; Huong, 2009; Wanjohi, 2009). One study showed that factors 
associated with poor adherence to antiretroviral therapy were young age, low income, 
low literacy, unstable housing, and homelessness (Machtinger & Bangsberg, 2006). 
Furthermore, women busy taking care of their children and those with psychological 
problems were associated with poor adherence (Kennedy, Goggin, & Nollen, 2004). 
Another study on gay men found that about three-quarters of the partcipants reported 
missed doses in the last six months and approximately one-third missed a dose in the 
last week (Shernoff, 2001). However, some previous finding showed that gender was 
not associated with ART adherence (Orrell, Bangsberg, Badri, & Wood, 2003; Erah, 
& Arute, 2008). Low education is a factor that leads to poor adherence because, for 
example, when patients are illiterate, they cannot understand and remember the 
explanation of counselors and physicians and sometimes they take ARVs mistakenly 
(Piot, Bartos, Ghys, Walker, & Schwartländer, 200). Also, another study in Togo 
showed that treatment knowledge and cognitive demands related to complex ART 
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regimens are important components of adherence to ART (Potchoo, Tchamdja, 
Balogou, Pitche, Guissou, & Kassang, 2010). However, previous research findings 
show that education and knowledge of ART were not statistically significantly 
associated with adherence (Markos, Worku, & Davey, 2008; Cauldbeck et al., 2009). 
Another contrasting finding is that family income (poverty status) was not 
significantly associated with adherence to antiretroviral therapy (Orrell, Bangsberga, 
Badri, & Wood, 2003; Cauldbeck et al., 2009). Moreover, some previous findings 
found that occupations are not significantly associated with ART adherence (Orrell, 
Bangsberga, Badri, & Wood, 2003; Markos, Worku & Davey, 2008). One previous 
research found that food is not significantly associated with ART adherence (Manary, 
Ndekha, & Van Oosterhout, 2010). 
1.1.2.2.4.3. Predictors related to disease characteristics 
Disease characteristics such as duration of HIV/AIDS, opportunistic 
infections and its symptoms as well as morbidity, World Health Organization (WHO) 
stages, CD4, and viral load are predictors of non-adherence (Machtinger & 
Bangsberg, 2006). For example, a study on symptom management for improving 
quality of life and drug adherence in HIV/AIDS patients found that an increase in 
CD4 count and low or undetectable viral load were influencing adherence to 
antiretroviral therapy (Wood, Hogg, Yip, Harrigan, O’Shaughnessy, & Montaner, 
2003; Chiou, Ing-Tiau Kuo, Lee, Chen, Chuang, & Lin, 2006). However, one 
previous research finding shows that CD4 count is not associated with ART 
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adherence (Erah & Arute, 2008; Ford, Darder, Spelman, Maclean, Mills & Boulle, 
2010). The higher the severity of disease the more pain patients suffer, however, the 
lower adherence level patients have. For instance, higher severity of disease 
including, WHO stage 3 and stage 4, was associated with poor adherence (Shah, et 
al., 2007). However, some previous research findings found that WHO stages are not 
statistically associated with ART adherence (Orrell, Bangsberga, Badri, & Wood, 
2003; Bajunirwe, Arts, Tisch, King, Debanne, & Sethi, 2009). 
1.1.2.2.4.4. Predictors related to clinical settings 
Clinical settings and health care services are one of the predictors of poor 
adherence. These include greater distances from health clinics to patients’ homes and 
working places; difficult transportation conditions, such as bumpy roads or roads cut 
by floods; expensive transportation fees, for example, too long or too frequent 
schedules and appointments with health care providers; long waiting time during 
hospital visits, poor quality of health care services; and especially low confidence in 
health care staff including nurses, counselors, physicians (Nakiyemba, 2005). 
Moreover, a study on barriers to adherence to antiretroviral therapy in Togo indicated 
that the cost of travel (transportation) and treatment accounts for about 26 and 14 
percent, respectively, to be the reasons for poor adherence (Potchoo, Tchamdja, 
Balogou, Pitche, Guissou, & Kassang, 2010). However, some previous research  
found that far distance from health care facilities was not significantly associated with 
poor adherence (Hardon et al., 2006; Cauldbeck et al., 2009). 
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1.1.2.2.4.5. Predictors related to other factors 
There are some other factors associated with poor adherence to ART such as 
lack of family members, friends, and social support; stigma and discrimination; no 
reminders or alarm clocks; alcohol as well as injecting drug use; and poor relationship 
between patients and health care providers. One study on barriers to ART adherence 
found that a lack of social support was associated with sub-optimal adherence to 
antiretroviral therapy (Williams & Friedland , 1997). Another study in three countries 
in Africa, including Botswana, Tanzania, and Uganda, reported that patients 
complained of lack of social support, felt isolated, abandoned, and even stigmatized 
from family members, friends, neighbors, and from others. These reasons were the 
main factors that influenced their poor adherence (Hardon, et al., 2006). Another 
study revealed that use of alcohol, drugs, and injecting drugs were also linked to sub-
optimal adherence (Grierson, Misson, McDonald, Pitts, & O’Brien, 2002). 
1.1.2.3. Adherence assessment 
Before the era of highly active antiretroviral therapy (HAART), many AIDS 
patients died, mainly due to opportunistic infections and other related AIDS-related 
diseases. Since HAART has been developed and given to AIDS patients, however, 
the number of HIV/AIDS patients dying is substantially decreasing. Moreover, 
HAART can improve the quality of life and survival of HIV/AIDS patients by 
reduction of CD4 destruction, HIV viral load in blood, opportunistic infections and 
other related diseases if patients adhere to ART plans well (Markos, Worku & Davey, 
2008). While poor adherence results in the development of HIV drug resistance, ART 
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failure, decrease in CD4 cell counts as well as low rate of HIV viral load in blood 
detection, high morbidity and mortality rate, eventually lower ART success. 
Adherence to ART is defined as sticking to the treatment plan by taking the 
correct dose of drugs at the correct time and in the correct way (such as with the right 
type of food or fluid). It also means looking after drugs to make sure they are safe and 
effective to use (Castro, 2005). 
ART cannot be successful unless adherence is optimal, at least 95 percent. 
This level is very difficult for HIV/AIDS patients to achieve because it requires high 
commitment and life-long treatment (Paterson et al, 2000; Castro, 2005). 
Adherence measurement is a challenging job for health care providers, 
especially counselors, in order to identify poor and good adherent patients. It depends 
on ART regimens, the availability of means of adherence assessment, and it varies 
from one country to another (developing country to developed country). To achieve 
ART success, an accurate assessment of adherence is necessary and patients require 
having at least 95 percent of adherence level (WHO, 2003). Currently, however, there 
is no gold standard to measure adherence to ART. For that reason, the researchers 
have developed and classified adherence assessments into two categories. The first 
category is direct and objective measures such as directly observed treatment, 
therapeutic drug monitoring, biomarkers, and medication event monitoring system. 
The second category is indirect measures, which consist of pharmacy records, pill 
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counts, self-reports, pill identification tests, and VAS (Steel, Nwokike, & Joshi, 
2007).  
It seems more likely that direct and objective measurement is more accurate 
and reliable than the indirect measurement of adherence. Despite that, poor resource 
settings cannot afford to use this measurement because it is more costly and 
complicated than indirect measurement. 
Although self-reporting has been found to overestimate adherence, VAS is 
still a simpler, cheaper, easier, valid and reliable tool to measure adherence to ART in 
resource-constrained settings (Walsh, Mandalia, & Gazzard, 2002).  
HIV/AIDS patients’ counselors at the Infectious Disease Department of 
Sihanouk Hospital Center of HOPE use both pill count and self-report (VAS) 
methods to measure adherence (Samnang & Soklida, 2010). Pill count is usually 
conducted at the hospital by requiring patients to bring their medications when they 
see counselors on each hospital visit. In order to assess adherence, counselors count 
the numbers of pills in the bottle and determine whether or not there are any missed 
doses by comparing the actual number of tablets that physicians have prescribed to 
patients. Finally, counselors report that patients have optimal (good) adherence if they 
missed fewer than or equal to three doses per month. In contrast, missing at least four 
doses in the last month before a patient’s visit represents sub-optimal (poor) 
adherence to ART. Though adherence measurement using pill count is likely to be 
more accurate than VAS, it still has some disadvantages. For example, patients may 
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not take their ARVs at home; they instead hide their tablets or throw them away and 
then they keep only the actual number of tablets needed to be shown to counselors. 
Additionally, while counselors may have completed the pill count and noted the data 
on the patients chart, the data are not then entered into a database as VAS is 
(Samnang & Soklida, 2010). 
 The Visual Analogue Scale (VAS) method was employed to measure self-
reported adherence of patients in the last month prior to their hospital visit by using a 
10-centimeter scale, which ranges from 0 cm to 10 cm on a ruler. The counselors ask 
patients to put a mark somewhere on the ruler and then counselors measure and 
compute it into percentages; 0 cm, the beginning of the ruler, shows that they have 
not taken their pills at all, while 10 cm, the end of the ruler, indicates that they have 
taken all their prescribed pills (Samnang & Soklida, 2010). For the purpose of study 
and research, the Infectious Disease Department of Sihanouk Hospital Center of 
HOPE asks counselors to collect VAS data, which have been collected at every 
patient’s visit. 
Based on the availability of VAS data in the cohort database of the 
Department, the author decided to choose VAS as a measurement of adherence and 
method of data collection on adherence in this study.  
1.1.2.4. Previous study findings 
As mentioned above, in general, poor adherence to medication is common 
throughout the world.  
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 It is estimated that around 50% of the world’s HIV/AIDS patients have taken 
their prescribed ART medications inappropriately (Paterson, et al., 2000). Adherence 
to antiretroviral therapy varies from 37-83% in relation with drugs under study (Steel, 
Nwokike, & Joshi, 2007). In addition, more than 10% of patients report missing at 
least one medication dose on a daily basis, while more than 33% report missing doses 
in the past two to four weeks (Chesney , 2000).  
Several studies have presented their adherence findings in developed countries 
as follows: According to the World Health Organization (2003), the level of 
adherence to chronic disease treatment was about 50% in the developed countries. 
One study in the United States of America found that 50 to 60 percent of HIV/AIDS 
patients failed to reach good adherence (greater than 95%) (Stone & Smith, 2004). 
The factors for poor adherence in that study were total pills per day, dosing 
frequency, dietary restrictions, pill size, number of prescription and medication, and 
bed time dosing. Another example of limited ART adherence of patients in Canada 
was found in a retrospective study with additional prospective component in which 
only 75% of patients had greater than 80% adherence to antiretroviral therapy. The 
reasons for missing doses were forgetfulness, dietary restrictions, inconvenient dosing 
schedule, and difficulty scheduling administration time around meals (Ostrop, Hallett, 
& Gill, 2000). 
 Some studies in the developing countries have found that adherence levels to 
ART were sub-optimal. The adherence level of one study on adherence to ART in 
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Brazil was only 75% (95% confidence interval 73.08-76.95). The factors for poor 
adherence were complex regimens, a large number of pills, illiteracy (under two-year 
study), and age less than 44 years (Nemes, Carvalho & Souza, 2004). In Africa, a 
number of studies have shown low levels of ART adherence. For example, the 
National AIDS and STI Control Program (NASCOP) of Kenya study on a review of 
records for a 20-month period indicates that 13 percent of the patients had left the 
area, had discontinued use of ART, or had died (Wanjohi, 2009). Another study 
estimated that one quarter (25%) of ART users did not achieve optimal adherence 
(Hardon et al., 2007). Of more concern, a recent systematic review of ART programs 
reported that about 40 percent of all patients receiving ARVs were thought to have 
died or discontinued their treatments within two years of treatment.  
There were several similar examples of poorer levels of adherence reported by 
Maria (2008): Studies on ART adherence in urban and rural areas in 2007 by the 
Catholic Diocese of Ndola, Zambia and Catholic Archdiocese of Mombasa, Kenya 
found that adherence levels were 60% and 76%, respectively. Also, the Ashar Alo 
society, Bangladesh found similar adherence levels in rural areas. Moreover, in 
Bolivia in 2007, the Instituto para el Desarrollo Humano reported that the adherence 
level studied by a local university was only 50%, which was the primary problem for 
antiretroviral therapy. In addition, data summarized by the Catholic Relief Service 
(CRS), from nine countries within their ART program from 2005 to 2007, showed 
that HIV/AIDS patients still had poor adherence to ART as follows: Kenya 6%, 
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Zambia 10%, Uganda 12%, and Nigeria 14% (Maria, 2008). The factors that 
influenced poor adherence in the studies reported by Maria (2008) were multi-
faceted, however, they, in general, had similar characteristics including the cost of 
transportation, laboratory tests, lost wages due to long waiting times, hunger and 
nutrition, the need for continuous support for patients on treatment, misinformation, 
side effects, and lifelong antiretroviral therapy.  
Also, a survey of 291 AIDS patients in Ethiopia showed that the prevalence of 
adherence in the week prior to the interview was 74.2%. The factors of non-
adherence to antiretroviral therapy were busyness or forgetfulness (51%), change in 
daily routine (9.4%), and being away from home (8.3%). Moreover, the most 
common reasons for poor adherence reported by patients were symptoms or side 
effects in the past four weeks, followed by living more than 47 km away from a 
health facility ( Markos, Worku, & Davey, 2008).  
Similarly, a cross-sectional study of 43 patients using the health facilities of 
the Center for Special Clinic in Sagamu, Nigeria reported that approximately 80 
percent of patients reached an adherence level of 95%. The most common reasons for 
non-adherence was the cost of drugs; however, socio-demographic variables and 
number of pills taken as well as dosing frequency per day were not significantly 
associated with poor adherence to antiretroviral therapy (Ogundahunsi, Daniel, & 
Oladapo, 2008). Poor adherence levels were also found in an evaluation of 
antiretroviral therapy results of 717 patients who had visited ART clinic in Blantyre, 
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Malawi. 59% of the total patients were lost to follow-up. Furthermore, during 
adherence interview, only 92 (52%) patients reported never missing a single dose of 
medication. The main reasons for loss to follow-up were unavailability of drugs, 
personal financial problems, and side effects of ART (Oosterhout, et al., 2005). 
Another example of poor adherence level was shown in a study of knowledge and 
adherence to antiretroviral therapy among adult people living with HIV/AIDS treated 
in the health care centers of the association ―Espoir Vie Togo‖ in Togo, West Africa. 
The study demonstrates that the average adherence rate was about 90 percent, while 
an adherence rate of greater than or equal to 95 percent was about 63 percent. Poor 
adherence was mainly due to forgetfulness, followed by travel, cost of treatment, and 
side effects of drugs; however, gender, age groups, educational levels, and ART drug 
regimens were not significantly associated with poor adherence (Potchoo, Tchamdja, 
Balogou, Pitche, Guissou, & Kassang, 2010).  
In Asia, sub-optimal (less than 95%) adherence level was also confirmed by 
the following studies. A study of 60 HIV/AIDS patients on ART in India found that 
only 60 percent of patients reported that they took their ARVs correctly (Cauldbeck, 
et al., 2009). Adherence was statistically significantly associated with regular follow-
up. Other factors, such as older patients, male gender, side effects, those from larger 
family, those who had previously AIDS defining illness, those taking fewer 
medicines and without food restrictions, were not statistically significantly linked to 
adherence, however, they had a positive trend. In contrast, level of education, family 
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income, distance from clinic, and time since diagnosis or time on ART had a negative 
trend away from adherence (Cauldbeck, et al., 2009). In addition, another study on 
adherence to antiretroviral therapy and virologic suppression among HIV-Infected 
persons receiving care in private clinics in Mumbai, India found that 73.5% of the 
total 279 participants reported adherence greater than or equal to 95% in the past four 
days, 16.1% and 10.4% took 70-94% and less than 70% of their prescribed doses, 
respectively. The main reasons for poor adherence were running out of pills, traveling 
away from home, feeling sick or ill, forgetfulness, and being busy with other things. 
Regimens-related factors significantly correlated with adherence were cost of ART 
per month, regimen with more than or equal to three antiretroviral drugs, and taking 
more than or equal to three pills per day. In addition, adherence was positively linked 
to age older than or equal to 50 years, co-morbid conditions, efficacy of medications, 
absence of pain in the last month, and support from family and friends. However, lack 
of reminders to take medications from family or friends, confusion of ART regimens, 
side effects of drugs, and presence of pain in the last month were negatively 
associated with adherence (Shah, et al., 2007). Another poor adherence level was also 
shown by a study on factors associated with adherence to antiretroviral therapy 
among HIV/AIDS patients in rural China. Of the total 181 participants, 81.8% 
reported ≥ 95% ART adherence on the previous three days. The main causes of 
missing doses included forgetfulness, being busy, and ART adverse effects. 
Furthermore, knowledge of patients of ART side effects, belief in the efficacy of 
ART, reminder tools of taking antiretroviral drugs, and confidence and trust of 
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patients in their health care providers were independently associated with adherence. 
While patient’s knowledge of ART and socio-demographic factors were not 
associated with adherence (Wanga & Wu, 2007).  
Likewise, several studies in South-East Asian countries have found poor 
levels of adherence to antiretroviral therapy as mentioned above. Taken as an 
example, a study on a review of records of all hospitals in Northern Thailand 
demonstrated that 246 of the 819 AIDS patients had dropped out from health facilities 
after six months on ART. The main factors for missing doses were side effects of 
medications, financial constraints, forgetfulness, better health condition, living away 
from home, being busy with many things, sleeping through dose time, and change in 
routine (Charukanya, 2008). Another study in Vietnam shows that 37 percent of 151 
patients adhered poorly (< 95%) to ART. The reasons for missing doses were 
forgetfulness, being busy, sleepiness, and stress. Moreover, results of multivariate 
analysis revealed that ten factors were statistically significantly associated with poor 
adherence, including the use of alcohol in the last one month, unemployment, use of 
drugs early or late, no reminders at home, no mention of reminder tools by doctors in 
the last three months, no counseling on HIV prior to starting ART, no effective 
support from spouses, fear of being exposed at the clinic, being less interested in the 
last seven days, and a detectable viral load above 400 copies/mL during interviews. 
However, socio-demographic factors such as gender, age, and marital status did not 
affect adherence to antiretroviral therapy (Huong, 2009). In Cambodia, the majority 
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of HIV/AIDS patients have performed good adherence; however, the remaining 
patients still have poor adherence levels (< 95%). Figure 1.5 below shows poor levels 
of ART adherence in three different settings in Cambodia. 
 
 
 
        
         
         
         
         
         
         
         
         
         
         This graph shows that Calmette Hospital has the worst level of ART 
adherence (29%), while nationwide, 13% of HIV/AIDS patients have poor adherence 
level. Sihanouk Hospital Center of HOPE (SHCH) has the best level of adherence, 
with only three percent of patients exhibiting poor adherence. 
As mentioned above, universal access to ART has increased substantially in 
order to meet the demand of HIV/AIDS patients in Cambodia and the rest of the 
world. To achieve antiretroviral therapy’s success, optimal adherence (≥ 95%) to 
ART must be reached. In fact, HIV/AIDS disease cannot be cured. Hence, it requires 
lifelong treatment which makes ART adherence a high concern in both developed and 
developing countries such as Cambodia. There has been so far no research conducted 
13
29
3
0
10
20
30
40
Nationwide Calmette SHCH
%
NAA, 2007; AIDS Rsearch and Treatment, 2010 & SHCH 2010
Figure 1.5: Poor levels of ART adherence in Cambodia
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on barriers to antiretroviral therapy in Cambodia. Therefore, a study on barriers to 
adherence of HIV/AIDS patients to antiretroviral therapy is needed. 
1.2. Research objectives 
1.2.1. Main objective  
The main objective is to identify barriers, which are associated with poor 
adherence to ART. 
1.2.2. Specific objectives 
The specific objectives are: 
 To identify if there are any ART side effects associated with poor 
adherence to ART. 
 To identify if there are any ART regimens associated with poor adherence 
to ART. 
 To identify if there are any co-opportunistic infection treatment drugs 
associated with poor adherence to ART. 
 To identify if there are any levels of patient knowledge of ART associated 
with poor adherence to ART. 
 To identify if there are any educational levels of patients associated with 
poor adherence to ART. 
 To identify if patient’s location of residence is associated with poor 
adherence to ART.  
 To identify if poverty is associated with poor adherence to ART. 
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 To identify if there are other socio-demographic and economic factors 
associated with poor adherence to ART. 
1.3. Research questions 
In order to meet the objectives above, one main question and eight 
specific questions were asked as follows: 
1.3.1. Main question 
What barriers are associated with poor adherence to ART? 
1.3.2. Specific questions 
 What ART side effects are associated with poor adherence to ART? 
 What ART regimens are associated with poor adherence to ART? 
 What co-opportunistic infection treatment drugs are associated with 
adherence to ART? 
 What levels of patient knowledge of ART are associated with poor 
adherence to ART? 
 What educational levels of patients are associated with poor adherence 
to ART? 
 Which patient’s location of residence is associated with poor 
adherence to ART? 
 What poverty status of patients is associated with poor adherence to 
ART? 
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 What other socio-demographic and economic factors are associated 
with poor adherence to ART? 
1.4. Research hypotheses  
 ART side effects may influence adherence to ART. 
 ART regimens may influence adherence to ART. 
 Co-opportunistic infection treatment drugs may influence adherence to 
ART. 
 Levels of patient knowledge of ART may influence adherence to ART. 
 Educational levels of patients may influence adherence to ART. 
 Patient’s location of residence may influence adherence to ART. 
  Poverty status of patients may influence adherence to ART. 
1.5. Significance of the study 
As mentioned above, poor adherence to ART is of high concern in developed 
and developing countries. By discovering barriers or factors, which are associated 
with poor adherence to ART in Cambodia and in SHCH, this study can first help 
practitioners and policy makers to improve the success of their ART program. 
Second, the study can improve the quality of life of HIV/AIDS patients by reducing 
burdens of HIV/AIDS disease, HIV drug resistance, ART failure, morbidity and 
mortality as well as offering them a good opportunity to live normally. Finally, this 
research is able to contribute to the Cambodian government through saving more 
money from spending on prevention of HIV transmission, patient care, treatment, 
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support, and other related managements so that the government can further alleviate 
the poverty of the Cambodian people as well as increase the opportunities to develop 
the country.  
1.6. Limitations and constraints of the study 
First, this study used a self-report method, the Visual Analogue Scale (VAS), 
which is a subjective tool, to assess patient’s adherence to antiretroviral therapy based 
on available data at the Infectious Disease Department of Sihanouk Hospital Center 
of HOPE. It may be less accurate than pill count technique, which is objective, to 
measure adherence, however, there were no available data of pill count at the study 
site. Second, study subjects were only focused on HIV/AIDS patients. It would be 
better if health care providers had also been included as the study subjects because 
they can make research findings more reliable. Third, this study was conducted only 
in one setting, Sihanouk Hospital Center of HOPE, which seems not to generalize 
other settings in the entire country. 
1.7. Organization of thesis 
This research is divided into four main chapters as follows:  
Chapter I provides a detailed description of (1) the rationale of the study 
which includes background of the study, literature review and problem statement, and 
conceptual framework, (2) research objectives, (3) research questions, (4) research 
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hypotheses, (5) significance of the study, (6) limitation of the study and (7) 
organization of thesis. 
Chapter II illustrates comprehensive processes in the study, which include 
study design, sampling methods, methods of data collection, ethical considerations, 
and data analysis. 
Chapter III elaborates on the research findings that are divided into two main 
parts. First, results are presented in a descriptive analysis embodying socio-
demographic and economic characteristics, knowledge of research participants of 
ART drugs, ART regimens and OI treatments of research participants, ART side 
effects of research participants, ART adherence characteristics and reasons reported 
for missing ARV doses in this study. Second, results of association between 
dependent and independent variable analysis are presented, including results of 
association between hypothesis testing and adherence to ART analysis and results of 
association between socio-demographic and economic factors and adherence to ART 
of analysis. 
Chapter IV describes (1) a brief summary of the problem statement; research 
objectives; research methods, which include study design, sampling methods, 
methods of data collection, and data analysis (2) discussions which focus on a 
summary and comparisons of the current research findings with those of previous 
research in accordance with results of reasons reported for missing ART doses in this 
study, results of hypothesis testing, and results of socio-demographic and economic 
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factors, (3) conclusions which are drawn from the main and significant findings of the 
study, (4) policy implications which involve a comprehensive intervention of 
improving ART adherence, and (5) finally suggestion for future research that needs to 
be conducted to fill up the gaps of the current study.  
 The Next chapter will explain research methods used in conducting this 
study. 
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CHAPTER II: RESEARCH METHODOLOGY 
2.1. Overview of research methodology 
This chapter explains in detail the overall procedures and methods used in the 
study. The chapter is divided into 13 main parts that include the study design, study 
area and time frame, target populations, study populations, sample populations, 
inclusion criteria, exclusion criteria, study variables, sampling procedures, methods of 
data collection, ethical considerations and administrative formalities, data processing 
and analyses, and finally a chapter summary. 
2.2. Study setting 
This study was conducted at Sihanouk Hospital Center of HOPE (SHCH) 
situated in Phnom Penh, the Capital City of Cambodia, with a population of about 
one million, the highest population density in the country, and is well known as the 
economic, public administration, political, education, tradition as well as culture, 
national and international trade, and entertainment centers. Sihanouk Hospital Center 
of HOPE has been operating since 1996, with a mission to be a center of excellence 
not only in providing further education and clinical training of medical professionals 
from both public and private health sectors in the country but also in providing 24-
hour-high quality, free medical care services to the poor, needy, and disadvantaged in 
Cambodia.  
The hospital has technical and administrative departments. The former 
includes anesthesia, emergency, information technology, laboratory, internal 
46 
 
medicine, medical records, nursing, physical therapy, radiology, hospitality, surgical, 
telemedicine, pathology, and infectious disease departments while the latter includes 
finance and procurement, communication and public relations departments. 
The Infectious Disease Department has operated since 1997, after the most 
widespread epidemic of HIV/AIDS occurred in Phnom Penh and other areas of the 
Royal Kingdom of Cambodia, with financial support from global funds. The 
department provides treatment of both opportunistic infection (OI) and antiretroviral 
therapy (ART) services to people living with HIV/AIDS (PLWHA). The number of 
HIV/AIDS patients on ART, by March 2010 was 2,467, of which 96 percent were on 
first-line ART (Sopheak, 2010). The majority of PLWHA (62.39%), who came to 
receive ART services at the hospital, were living in Phnom Penh. 
The decision to choose Sihanouk Hospital Center of HOPE as the study site 
was made because it is the setting where HIV/AIDS patients come to receive ART 
program services from many different places of Cambodia, which can generalize the 
characteristics of the HIV/AIDS patients of the whole country. Moreover, the author 
used to work there for four years such that he is familiar with the hospital 
management system as well as hospital staff and patients so that he had easy access to 
conducting the study. 
2.3. Study design and time frame 
A comparative cross-sectional survey in the form of a case-control study of 
poor ART adherent patients as cases against a control group of good ART adherent 
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patients was conducted at Sihanouk Hospital Center of HOPE from August 16 to 
September 30, 2010. This research embodies both a quantitative and qualitative 
perspective in order to provide high quality results based on close-ended questions 
and open-ended questions in the questionnaire. The close-ended questions involve 
numbers, which represent a quantitative research perspective, while open-ended 
questions provide a qualitative research perspective, which seeks for reasons 
expressed in words behind any study problems.  
2.4. Research subjects 
2.4.1. Target population 
The target population was all HIV/AIDS patients at SHCH. 
2.4.2. Study population  
The study population was all HIV/AIDS patients who were on ART at 
Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia.  
2.4.3. Sample population 
The sample population consists of 60 poor ART adherent patients and 57 
good ART adherent patients. Among the sample population, females represent the 
majority, 61.5 percent, because more female than male patients had received ART at 
the hospital. 
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2.4.4. Inclusion criteria 
The inclusion criteria of the research subjects include adult (equal to or older 
than 15 years old) HIV/AIDS patients who were at least six months on ART, with 
informed consent signed and agreed to participate in the study. 
2.4.5. Exclusion criteria  
The exclusion criteria of the research subjects include:  
 HIV/AIDS patients who were on ART less than six months 
 HIV/AIDS patients who were younger than 15 years old. 
 HIV/AIDS patients who had not started ART. 
 HIV/AIDS patients who had had mental problems and had been 
seriously sick. 
2.5. Study variables 
Study variables are divided into two categories: the dependent variable and 
independent variables. 
 The dependent variable is adherence to ART of the HIV/AIDS patients 
which could be either poor or good. 
 Independent variables consist of attributes that may lead to either poor 
or good ART adherence which are those listed in the table below. 
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Independent variables 
Table 2.1: List of studied independent variables 
Hypothesis testing Variables 
 
ART side effects 
 
ART regimens 
 
OI drug uses 
 
Knowledge of ART 
 
Educational levels 
 
Patient's location of 
residence 
 
Poverty 
Socio-demographic and economic factors Variables 
 
Gender 
 
Age groups 
 
CD4 groups 
 
WHO stages 
 
Marital status 
 
Occupations 
 
Food 
 
2.6. Sampling procedures and methods 
2.6.1. Sampling technique 
There are two major sampling methods in social science. These are non-
probability and probability sampling. The non-probability sampling represents any 
techniques in which sample selection is not based on the probability theory. Some 
examples of non-probability sampling are purposive, snowball, and quota sampling 
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(Babbie, 2005). Probability sampling, however, is any techniques whose sample 
selections are based on the probability theory. It typically involves some random 
selection mechanisms such as simple random sampling, systematic random sampling, 
and stratified random sampling (Babbie, 2005).  
The objectives of social research, mainly, are to generalize research findings 
from the study sample to the larger population and to avoid biases. For that reason, 
the availability of population as well as precise statistical predictions is very crucial 
(Babbie, 2005). 
Purposive and simple random samplings were used in this study for two 
reasons. First, purposive sampling was employed based on a small number of poor 
adherent patients identified under ART program from its beginning to March 2010 at 
Sihanouk Hospital Center of HOPE. Second, simple random sampling (SRS) was 
used among good adherent patients whose numbers are much larger than those of 
poor adherent patients. Moreover, SRS is the probability sampling that can reduce the 
bias of sample selection since it can provide each research respondent with an equal 
chance of being selected for the study. 
Prior to the interview, the author had discussed with counselors and medical 
recorders (clerks) the tactic to capture patients, who were to be included in the study, 
after receiving a list of patient names. First, counselors singled out all patients easily 
because they have worked at the Infectious Disease Department of Sihanouk Hospital 
Center of HOPE for many years and their responsibilities were to counsel with 
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HIV/AIDS patients every day. Second, clerks had put an alarm signal on any patient’s 
computer records if that patient had been shortlisted for interview so as to double 
check and capture comprehensively all the names of patients.  
2.6.2. Sample size 
Since the Infectious Disease Department of Sihanouk Hospital Center of 
HOPE has operated until March 2010, the total number of HIV/AIDS patients under 
ART program was 2,417, of which 74 (3%) represented patients with poor adherence 
to ART (Sopheak, 2010). 
Based on a small number of poor adherent patients, the author chose to use 
purposive sampling in a bid to have a bigger sample out of these poor adherent 
patients. As a result, 60 poor adherent patients were identified. The remaining poor 
adherent patients had not participated in the study because of inability to contact with 
them; others lived far away from the research site or just recently had the 
appointment with physicians prior to the interview.  
Simple random sampling was used to select samples from good adherent 
patients who came to visit the hospital to receive ART, following their appointments 
with physicians. The number of good adherent patients, who came to see doctors 
every day, on average, was about 70-100. The simple random sampling was 
conducted every day among good adherent patients, by putting their names in a hat, 
then shaking the hat, and picking up a number of lotteries of patients’ names from the 
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hat in terms of required number of the patients for the author. After SRS ended, 57 
samples of good adherent patients were selected.  
As the research design is a comparative cross-sectional in the form of case-
control study, a group of 60 patients who had shown poor adherence was compared 
with a control group of 57 random patients with good adherence to ART. Therefore, 
117 HIV/AIDS patients are included in the study.  
2.7. Methods of data collections  
 Both quantitative and qualitative approaches were used to collect data in this 
study. In general, there was a variety of techniques used to collect data such as tests 
and measurements, observations, surveys, documents, and interviews that can help 
the author reach the objectives of the study (Glatthorn & Joyner, 1993). A face-to-
face interview followed a structured questionnaire, as well as both primary and 
secondary data collection methods was used to conduct this research. 
2.7.1. Primary data collection 
All eligible respondents who met the inclusion criteria and signed the 
informed consent were included in the study. The primary data were obtained by 
face-to-face interviewing of both poor and good ART adherent patients, followed by 
a self-administered and structured questionnaire to answer research questions.  
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2.7.2. Secondary data collection 
The secondary data used in the literature review and analysis were collected 
from the database cohort of the Infectious Disease Department of Sihanouk Hospital 
Center of HOPE, annual reports, monitoring and planning, research, and documents 
of the National Center for HIV/AIDS, Dermatology, and STD (NCHADS), UNAIDS, 
WHO, United Nations Children’s Fund (UNICEF), and other related research of both 
local and international institutions. 
2.7.3. Data collection on adherence to ART 
Figure 2.1: Data collection on ART adherence at SHCH
by March 2010
Source: Infectious Disease Department Database
2467 PLWHA on ART
First line ART 
2373(96%)
2426 VAS
75(3%) poor adherent  PLWHA
Second line ART 
94(4%)
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At the Infectious Disease Department of Sihanouk Hospital Center of HOPE 
since the beginning of the program started from 1997 to March 2010, there were 
2,467 patients on ART. Of these patients, 96 percent were on first-line ART, while 
four percent were on second-line ART. However, out of the total 2,467 patients, only 
2,426 VAS were conducted, of which three percent were poor adherent patients, 
while the rest, 97 percent, was good adherent patients. For more detail on VAS, 
please see adherence assessment in Chapter I. 
 2.7.4. Research instruments  
As mentioned above in this section, there is a variety of tools used to collect 
data in social sciences. A face-to-face interview, followed by a structured 
questionnaire through a pre-test questionnaire and a pilot study, was conducted in the 
study of barriers to adherence of HIV/AIDS patients to antiretroviral therapy at 
Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia. 
2.7.4.1. Structured questionnaire 
A self-administered and structured questionnaire, with both closed and open-
ended questions, was designed in this study by using four previous studies. The first 
study was factors that influence non-adherence to antiretroviral therapy among HIV 
and AIDS patients in central province, Kenya (NYAMBURA, 2009). The second 
study was an evaluation of determinants of adherence to antiretroviral therapy in 
AIDS patients in Gert Sibande District, Mpumalanga Province (Laszchenov, 2009) . 
The third study was adherence to ART in PLWHA at Yirgalem Hospital, South 
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Ethiopia (Endrias, Alemayehu, & Gail, 2008). The last study was adherence to 
antiretroviral therapy among HIV patients in Bangalore, India (Mary et al., 2009). 
Next, the questions used in the two studies above were adjusted and combined 
together in order to develop a synthesized as well as reliable questionnaire in this 
study. The structured questionnaire can provide data, which are objective, scientific, 
precise, and reliable for hypothesis testing (Ong, 1993). 
The questionnaire consists of five main sections: socio-demographic and 
economic characteristics, knowledge of ART drugs, ART regimens and OI drug 
treatments, ART side effects, and characteristics of ART adherence and reasons 
reported for missing ART doses.  
The first section, socio-demographic and economic characteristics, focuses on 
gender, age groups, CD4 groups, WHO stages, marital status, education background, 
occupation, income, patient’s location of residence, and poverty as well as food 
access status.  
The second section, knowledge of ART, is comprised of six questions such as 
why do you take ARV drugs? How many ARV drugs need to be taken together for 
effective treatment? How long is the ARV treatment? What are the side effects that 
may happen during ART? What will you do if side effects happen? The last question, 
what are the benefits of taking ARVs regularly, continuously, and correctly?  
The third section, ART regimens and OI drug treatment, was made up of three 
questions, including what ART regimen are you currently on? What other drugs 
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besides ARVs are you currently on? The last question, do you have difficulty taking 
ARVs while using OI drugs? 
The fourth section, ART side effects, has three questions including did you 
experience ART side effects? What are the side effects that you experienced? Did 
side effects cause you to stop taking ARVs? 
The last section, factors influencing adherence to ART, consists of four 
questions: do you take ARVs regularly, continuously, and correctly? What are the 
factors that help you take ARVs correctly? What causes you not to take your tablets?  
Last question, many people find it difficult to take every single dose of ART; in the 
last month (prior to the interview date), how many doses did you miss? 
2.7.4.2. Pre-test questionnaire and pilot study 
Furthermore, a pilot study was conducted with five HIV/AIDS patients from 
each group (poor and good adherent group) on August 2, 2010, two weeks prior to the 
interview date. These ten patients were not included in the study in order to avoid any 
biases, which may occur in the research. Before the pilot study was undertaken, a pre-
test questionnaire was translated into Khmer, the local language, and then it was sent 
to a colleague who has many years of experience working with HIV/AIDS patients 
and currently is a clinical supervisor at the Infectious Disease Department of 
Sihanouk Hospital Center of HOPE, which is the research site. Therefore, the 
colleague is familiar with the Infectious Disease Department flow, management, and 
the interview process.  
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There are four purposes of conducting the pilot study. First is to test the 
questionnaire whether it makes sense and is easily understandable or not for research 
respondents. Second is to measure how long it takes for conducting the interview. 
Third is to adjust as well as modify words, sentence structures, any other grammatical 
mistakes, questions, and the entire questionnaire. Last is to learn, understand, pre-
examine, and to predict what would happen during the process of actual field 
research.  
After the pilot study was conducted, some words, written expressions, 
sentence structures, questions, and answers of the questionnaire were edited and 
changed to make them simple, precise, and more comprehensive to the research 
subjects. 
2.7.4.3. Interview with patients having poor and good adherence to ART 
Interview is one of the main methods used to collect data in many kinds of 
research. It consists of several forms such as face-to-face interview, focus group 
discussion interview, and telephone interview. The face-to-face interview through a 
self-administered and structured questionnaire, without exception, was employed to 
collect data in this study. There are four reasons to choose this interview approach. 
First, there is a limitation of research respondents’ knowledge to fill up the 
questionnaire since the majority of Cambodian people have low literacy rate, 
especially those from the countryside and HIV/AIDS patients. Second, the author can 
have the best opportunity to explain and clarify in detail both any doubts or questions 
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from the respondents and questions, answers as well as contents in the questionnaire. 
Third, the interview can allow the author to receive a high response rate from 
respondents. It is more likely that while staying and talking together with the 
interviewer, respondents are able to answer questions and fill up the questionnaire. 
Last, the author, at the same time, can play two roles in both interviewing respondents 
and observing their behavior directly. Hence, the interviewer can learn and better 
understand the situation of interviewees that may occur during the interview.  
Furthermore, the interview section is divided into two parts: interviewer and 
interview process. 
2.7.4.3.1. Interviewer (the author)  
The interviewer used to work with HIV/AIDS patients at the Infectious 
Disease Department of Sihanouk Hospital Center of HOPE for four years. For that 
reason, he has plenty of experiences providing voluntary confidential counseling and 
testing (VCCT), treatments as well as care services, and other related managements to 
HIV/AIDS patients. Therefore, he is not only familiar with the flows and 
management system of the hospital but he also knows most of the patients who came 
to receive ART service program. Eventually, the author was able to interview study 
subjects with high response as he expected. 
2.7.4.3.2. Interview process 
Before going to Cambodia, the author has received official permission letters 
from the Head of the Infectious Disease Department and director of Sihanouk 
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Hospital Center of HOPE and from the National Ethics Committee for Health 
Research of the Ministry of Health of Cambodia. After arriving in Cambodia, the 
author contacted the Head of the Infectious Disease Department of the hospital in 
order to discuss the interview and field research process with respondents. After a 
detailed and thorough discussion, the Head of the Department assigned a counselor to 
facilitate the interview since the counselor is responsible for working and counseling 
with patients every day. Hence, he is very familiar with respondents.  
Most of the respondents had appointments with physicians during the 
interview period; however, some respondents had their appointments before and after 
that period. In order to get enough sample size for the study, the author needed to 
contact, telephone, and make an appointment with those respondents whose follow- 
ups were not in the period of study before the interviews took place.  
 With full support and good cooperation from the Infectious Disease 
Department’s staff, including the Head of the Department, Head of the Department 
assistant, database manager, physicians, counselors, medical recorders, and nurses, 
the interviews with poor and good adherent patients on ART were conducted 
smoothly and lasted 45 days starting from August 16 to September 30, 2010 in a 
separate, private, and confidential room at the Infectious Disease Department of 
Sihanouk Hospital Center of HOPE.  
At the beginning of the interviews, the author provided a self-introduction, 
clear and detailed explanation of the topic as well as purposes of the study, the 
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duration of the interview, and informed consent to survey subjects. Also, the author 
had made them aware that they could choose to participate in or to quit the interview 
at any time if they did not want to answer questions. Having fully understood the 
overall content of the study, all 117 respondents accepted and agreed to sign the 
consent form. Therefore, 117 HIV/AIDS patients were included as a survey sample in 
this study.  
The author conducted face-to-face interviews through a self-administered and 
structured questionnaire with all respondents who were included in this study. On 
average, the interview with each respondent took approximately 20-30 minutes in 
order to obtain detailed information. However, it took a longer time with respondents 
who had a low level of knowledge and difficulty in understanding questions and 
answering questionnaire. In fact, the interviews with respondents were conducted 
with full respect and regard to ethical considerations and administrative formalities. 
2.8. Administrative formalities and ethical considerations 
This section is divided into two parts: administrative formalities and ethical 
considerations. 
2.8.1. Administrative considerations 
In Japan, the request letter to do field research in Cambodia was approved by 
the author’s supervisor, GHOTBI Nader, and the academic office of Ritsumeikan 
Asia Pacific University (APU).  
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Moreover, the author had written and submitted necessary documents to the 
Infectious Disease Department of Sihanouk Hospital Center of HOPE as follows:  
 The author’s request letter to Dr. Thai Sopheak, Head of the Infectious 
Disease Department of Sihanouk Hospital Center of HOPE and Mr. Kevin 
O’ Brien, Executive Director of Sihanouk Hospital Center of HOPE  
 Recommendation letter from the supervisor of Public Health Management 
Program of APU to Sihanouk Hospital Center of HOPE to conduct field 
research (appendix 3) 
 Summary of the study protocol in English and in Khmer 
 Detailed study protocol in English 
 Questionnaire in English and in Khmer 
 Consent form in English and in Khmer 
Also, the following compulsory documents were written and submitted to His 
Excellency Professor ENG Huot, Chairman of the National Ethics Committee for 
Health Research of the Ministry of Health of Cambodia. 
 The author’s request letter for conducting field research at Sihanouk 
Hospital Center of HOPE 
 Recommendation letter from the supervisor of Public Health Management 
Program of APU to National Ethics Committee for Health Research of 
Cambodia to conduct field research (appendix 4) 
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 Cover letter on submission of study protocol to the National Ethics 
Committee for review 
 Application form 
 Summary of the study protocol in English and in Khmer 
 Detailed study protocol 
 Questionnaire in English (appendix 2) and in Khmer  
 Consent form in English (appendix 1) and in Khmer 
 Permission letter from Sihanouk Hospital Center of HOPE   (appendix 5) 
 The author’s CV 
In Cambodia at Sihanouk Hospital Center of HOPE, Dr. Thai Sopheak, Head 
of the Infectious Disease Department and Mr. Kevin O’ Brien, Executive Director of 
Hospital approved the author’s request and permitted him to conduct field study at the 
Hospital. Furthermore, His Excellency Professor ENG Huot, Chairman of National 
Ethics Committee for Health Research of the Ministry of Health of Cambodia also 
approved the author’s request and proposal to do field research at Sihanouk Hospital 
Center of HOPE. Finally, the permission letter for conducting field research was 
authorized by the President of National Ethics Committee for Health Research of 
Cambodia (appendix 6). 
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2.8.2. Ethical considerations 
Ethical conduct is one of the key elements of the entire research process that   
needs to be maintained throughout the study. Every effort to protect the health and 
rights of the research subjects must be made (World Health Organization, 2004) .  
In order to adhere to the ethical conduct for health research, in this study 
informed consent was sought from the study population during the field data 
collection because HIV/AIDS is one of the most sensitive issues in medical research. 
Therefore, anonymity and confidentiality of the study subjects must be guaranteed. 
For this reason, a number of measures were taken: 
 No names and other related information of all study subjects were 
recorded in the questionnaire or other documents. 
 The privacy of all study subjects was protected during the interview 
session. 
 The subjects had the rights to refuse or withdraw if they do not want to be 
included in study sample. 
 The participation of the study subjects was voluntary. 
 The information and data collected in the questionnaire from the 
interviews have been kept in safe manner and will be destroyed after data 
have been entered, double checked, and analysis.  
 Nobody can access the study subjects’ information, except for the author. 
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 No money or any forms of goods were provided to research respondents in 
order to avoid any biases of the study. 
At the end of the interview, every research subject would receive words of 
appreciation and gratitude as well as a final assurance of anonymity and 
confidentiality from the author. 
2.9. Data analysis 
 This section is classified into four main parts. The first part is data 
organization, management, displays, and statistical package SPSS analysis. The 
second part is descriptive data analyses. The third part is hypothesis testing and Chi-
square test for association analyses. The last part is socio-demographic and economic 
factors and Chi-square test for association analyses. For further detail of each part, 
please see its descriptions and explanations as follows: 
2.9.1. Data organization, management, and displays using statistical package SPSS 
analysis 
This section explains the procedure by which data for statistical analysis were 
constructed. The procedure of converting the original responses in the survey to the 
variables (data) used in the statistical analysis consists of five steps. First, the 
questionnaire used in the interviews was written in Khmer (local language) in order 
for the research respondents to easily understand the overall meanings and contents of 
the questionnaire. Second, after the questionnaire was successfully completed, the 
author double-checked the answered questionnaire before translating it into English. 
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Third, all data in the questionnaire were coded, sorted, and grouped according to the 
study variables and purposes of the author’s study after they were entered into 
Microsoft Excel file, cross-checked, inspected, and scrutinized so as to ensure 
accuracy, relevance, completeness, consistency, and uniformity of collected data. 
Fourth, after the data in Microsoft Excel file were carefully and thoroughly 
cleaned, they were transported into statistical package SPSS file. Finally, data were 
again coded, sorted, and grouped into a concrete and precise organization before they 
were analyzed using Statistical Package SPSS software version 18.  
2.9.2. Descriptive data analysis 
Descriptive data analysis provides basic information, overall features, and 
characteristics of research respondents in the study. The descriptive data analyses 
mainly focus on five major parts. 
First data analysis involves socio-demographic and economic characteristics 
of research respondents, which focus on gender, age groups, CD4 groups, WHO 
stages, marital status, educational levels, occupations, patient’s location of residence, 
and economic and food access status of research respondents.  
Second data analysis focuses on knowledge of research respondents on ART, 
which concentrates on assessing their knowledge, and understanding of the overall 
benefits and contents of antiretroviral therapy (ART). Six questions were asked in 
order to assess knowledge of ART, which include why do you take ARV drugs? How 
many ARV drugs need to be taken together for effective treatment? How long is the 
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ARV treatment? What are the side effects that may happen during ART? What will 
you do if side effects happen? And the last question was, what are the benefits of 
taking ARVs regularly, continuously, and correctly?  
Third data analysis encompasses ART regimens, OI drug treatments, which   
centers on ART regimens and OI drug treatments that research respondents had taken, 
and also on any difficulties that could occur while concomitantly using these two 
treatments. Additionally, three main questions were asked to research respondents: 
what ART drugs are you currently on? What other drugs besides ARVs are you 
currently on? The last question was, do you have difficulty taking ARVs while using 
OI drugs? 
Fourth data analysis focuses on ART side effects that look for any side effects 
of ART that may have a relationship with adherence to ART. For that reason, three 
questions were asked: did you experience ART side effects? What are the side effects 
that you experienced? Did side effects cause you to stop taking your medicines? 
Last data analysis involves ART adherence characteristics and reasons 
reported for missing ARV doses in this study, which focus on seeking any factors that 
may affect adherence of the HIV/AIDS patients while taking ARVs. In order to 
determine these factors, four questions were asked: Do you take ARVs regularly and 
correctly? What are the factors that help you take ARVs regularly and correctly? 
What causes you not to take your tablets? Many people find it difficult to take every 
single dose; in the last month, how many doses have you missed? 
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Moreover, several methods of reporting data in these analyses are included 
such as raw data, frequency, and percentages. Finally, data are displayed using charts, 
graphs, tables, figure, and others. 
2.9.3. Hypothesis testing and Chi-square test for association analysis 
In order to understand this section, the definition of hypothesis and hypothesis 
testing is given. Lang and Secic (Lang & Secic, 1997, p. 261) state that: 
―Hypothesis is a statement that will be accepted or rejected on the 
basis of the results of the study, while hypothesis testing is a mathematical 
process of testing a hypothesis on the basis of evidence (data).‖  
 Since the objective of this study is to find out barriers to antiretroviral therapy 
(ART) adherence of HIV/AIDS patients at Sihanouk Hospital Center of HOPE, 
Phnom Penh, Cambodia, therefore, the dependent variable is adherence status to ART 
(poor and good adherence) and the independent variables include ART side effects, 
ART regimens, OI drug treatments, knowledge of ART, educational levels, patient’s 
location of residence, and poverty status (poor and not poor). 
Both dependent and independent variables in this study are categorical 
variables. The dependent variable is dichotomous (poor adherence and good 
adherence), while the independent variables are nominal variables. Chi-square test is 
used to assess relationships between two categorical variables (Godfrey, 1997) after 
cross-tabulation was done. In this study, the level of significance test used was 5% 
68 
 
(alpha level=0.05). Hence, a P-value less than 0.05 shows a statistically significant 
association between two categorical variables. 
Seven hypotheses were tested in this study: 
 ART side effects can influence adherence to ART. 
 ART regimens can influence adherence to ART. 
 OI drug treatments can influence adherence to ART. 
 Knowledge of ART can influence adherence to ART. 
 Educational levels can influence adherence to ART. 
 Patient’s location of residence can influence adherence to 
ART. 
 Poverty can influence adherence to ART. 
In these analyses, methods of reporting data are raw data, frequency, and 
percentages. Then, data are displayed using figures, cross-tabulations, and 
contingency tables. 
2.9.4. Socio-demographic and economic factors and Chi-square test for association 
analysis 
The Socio-demographic and economic factors apart from those tested in 
hypotheses above were also assessed by Chi-square test for association analysis in 
order to identify any relationships with adherence to ART. These factors were gender, 
age groups, CD4 groups, WHO stages, marital status, occupations, and food access 
status. 
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In these analyses, methods of reporting data are raw data, frequency, figures, 
and cross-tabulations. 
2.10. Chapter summary 
This chapter explained detailed procedures of the survey. It describes three 
steps of field research. First, how the questionnaire was designed, developed, and 
checked in a pilot study before the field research was conducted. Second, how the 
study sample was selected as well as how the interviews and methods of data 
collections were decided during the field research process. Finally, the chapter 
elaborated on data management and analyses using statistical software SPSS after the 
research field was done.  
The next chapter presents the results obtained with those methods. 
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CHAPTER III: RESEARCH FINDINGS 
3.1. Overview of research findings 
The results and data interpretations are presented in this section. The findings 
section is divided into two main parts. The first part is descriptive statistics results 
that consist of five sub-major parts including socio-demographic and economic 
characteristics, knowledge of research participants on ART, ART regimens and OI 
drug treatments, ART side effects of research participants, and ART adherence 
characteristics and reasons reported for missing ARV doses. The second part is 
statistically analyzed results of a test for association between two categorical 
variables that comprises hypothesis testing, and socio-demographic and economic 
factors. Moreover, hypothesis testing includes results of association using Chi-square 
test between ART side effects and adherence to ART, ART regimens and adherence 
to ART, OI drug regimens and adherence to ART, Knowledge of research 
respondents on ART and adherence to ART, educational levels and adherence to 
ART, patient’s location of residence and adherence to ART, and finally between 
poverty and adherence to ART. 
3.2. Results of descriptive analysis 
3.2.1. Socio-demographic and economic characteristics 
A survey of 117 HIV/AIDS patients, who had been at least six months on 
ART, was conducted at Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, 
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Cambodia. Of the 117 sample, 60 patients showed poor adherence and 57 patients 
good adherence to ART.  
3.2.1.1. Gender of research participants 
Figure 3.1. Gender of research participants 
 
 This pie chart shows that the majority of all research participants, 61.5 
percent, were females, while the remaining 38.5 percent were males. The males are 
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believed to be the main cause of transmitting HIV to females through heterosexual 
relations, especially from husband to wife at the household level.  
3.2.1.2. Age groups of research participants 
Figure 3.2: Age groups of research participants 
         
This graph shows that age groups 30-34 and 35-39 years old accounted for 
about 23 and 24 percent, respectively. While age groups 40-44 and older than 44 
years old were almost the same, about 20 percent. The age group younger than 30 
years old, however, was the smallest one, about 13 percent. 
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3.2.1.3. CD4 groups of research participants 
Table 3.1: CD4 groups 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid CD4 group 1-99 66 56.4 56.4 56.4 
CD4 group 100-199 22 18.8 18.8 75.2 
CD4 greater than 
199 
29 24.8 24.8 100.0 
Total 117 100.0 100.0  
 
This table reveals that CD4 group 1-99 accounted for the majority, about 56 
percent, while CD4 group 100-199 belonged to approximately 19 percent. These CD4 
groups prove that most of the HIV/AIDS patients have very weak immunity that 
makes them vulnerable to opportunistic infections. The CD4 group greater than 199 
accounted for about 25 percent. Patients, who have higher CD4, are most likely to 
have better protection from opportunistic infections. 
3.2.1.4. WHO stages 
Figure 3.3 illustrates that about 44 and 35 percent of HIV/AIDS patients, who 
were on ART, belonged to the seriousness of disease WHO stages 3 and stage 4 
respectively, while stage-1 patients accounted for only 6 percent. This shows that 
patients start ART when the severity of the disease has already increased.  
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Figure 3.3: WHO stages of research participants 
 
3.2.1.5. Marital status of research participants 
               Table 3.2: Marital status of research participants 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Single 8 6.8 6.8 6.8 
Married 69 59.0 59.0 65.8 
Divorced 24 20.5 20.5 86.3 
Others 16 13.7 13.7 100.0 
Total 117 100.0 100.0  
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This table indicates that most of the respondents (59 percent) were married, 
whereas 20.5 percent were divorced. The remaining marital statuses such as widowed 
and co-habiting patients accounted for 13.7 percent. 
3.2.1.6. Educational background of research participants 
Figure 3.4: Educational level of Research Participants 
 
This pie chart demonstrates that about 26 percent of the total research 
respondents were illiterate, who cannot read and write at all. About 34 percent of the 
patients had attended primary school, while about 23 percent had studied at secondary 
school. Attending high school or university, however, accounted for only about 16 
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percent. Moreover, the trend of studying at higher institutions was decreasing. In 
general, the educational level of the patients is still limited. 
3.2.1.7. Occupation of Research Participants 
Figure 3.5: Occupation of research participants 
              This bar chart indicates that, of all patients, 26 percent were operating small 
businesses or self-employed, while unemployed and company workers accounted for 
about 23 and 21 percent, respectively. Other categories such as NGO staff, restaurant 
and construction workers, and motor taxi drivers accounted for 12 percent. 
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3.2.1.8. Location of residence of research participants 
Figure 3.6: Patient’s location of residence 
 
This pie chart shows that most of patients (62 percent) lived in the Capital 
City, Phnom Penh, where the research facility is situated, while the remaining, 38 
percent, lived in provinces, which is more than 30 kilometers away from the research 
site. Currently, the number of Cambodian people moving from countryside and 
provinces to live in Phnom Penh is increasing due to lack of jobs in the rural areas. 
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3.2.1.9. Economic and food status of research participants 
Table 3.3: Economic status 
 
 Frequency Percent Valid Percent Cumulative Percent 
Valid Poor 82 70.1 70.1 70.1 
Not poor 35 29.9 29.9 100.0 
Total 117 100.0 100.0  
Table 3.4: Food access status 
 
 Frequency Percent Valid Percent Cumulative Percent 
Valid Enough 68 58.1 58.1 58.1 
Not enough 49 41.9 41.9 100.0 
Total 117 100.0 100.0  
Table 3.3 shows that the majority of the patients, 70 percent, were very poor, 
earning less than 1US$ (1US$=4000 Riel, local currency) per day.  
Table 3.4 reveals that 42 percent of the total participants did not have enough 
food to eat every day, which is higher than the poverty rate in Cambodia. It shows 
that there is an urgent need for food provision and financial support to the patients. 
3.2.2. Knowledge of research participants of ART drugs 
To assess the knowledge of ART drugs among the patients, the author 
provided a score to each question answered by the participants in the knowledge of 
ART drug section. There are in total six questions in the section. Then, the total score 
of all answers to the six questions was summed up. Knowledge of ART drugs was 
divided into two parts. The first part is low knowledge, score equal to or less than 14 
and the second part is high knowledge, score equal to or more than 15.   
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Six questions were asked to investigate whether the patients know about ART 
or not. Most of the patients had good knowledge of ART.  
3.2.2.1. Why do you take ART drugs? 
 
Figure 3.7 demonstrates that almost all patients (98.3 percent) responded that 
they took ARVs not for curing HIV/AIDS but for prolonging life or for stopping the 
progression of HIV/AIDS. Only one patient of the samples said he took ARVs to cure 
HIV/AIDS. In addition, 81.2 percent said they took ARVs to reduce pain. The answer 
as ―others‖ accounted for about 50 percent, which represents mostly good health, 
followed by increase in CD4, reduction of HIV viral load in the blood as well as HIV 
transmission, prevention of opportunistic infections, and prevention of mother-to-
child transmission of HIV (PMTCT). 
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Figure 3.7: Purposes of taking ARVs
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3.2.2.2. How many ARV drugs need to be taken together for effective treatment?  
Table 3.5: ARV drugs need to be taken together for effective treatment 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid One ART drug 11 9.4 9.4 9.4 
Two ART drugs 12 10.3 10.3 19.7 
Three ART drugs 93 79.5 79.5 99.1 
Others 1 0.9 0.9 100.0 
Total 117 100.0 100.0  
 
This table illustrates that about 80 percent of the patients responded with the 
right answers, saying that they need three ART drugs. The remaining 20 percent of 
the patients, however, provided wrong answers. 
3.2.2.3. How long is the ARV treatment?  
Table 3.6: ARV treatment duration 
 Frequency Percent 
Valid 
Percent Cumulative Percent 
Valid Lifelong 117 100.0 100.0 100.0 
 
 
Strikingly, all interviewed patients said that ARV treatment is lifelong, which 
is the correct answer.   
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3.2.2.4. What are the side effects that may happen during ART?  
 
This figure shows that almost 100 percent of respondents were sure that the 
side effect of ART was lipodystrophy, which is the atrophy of the muscle. Patients 
remember this side effect because it can affect their beauty such as face and buttock 
thinning while taking ARVs for at least six months.  
3.2.2.5. What will you do if side effects happen?  
Table 3.7 demonstrates that going to hospital was the best way when side 
effects occur. Among several possible answers, 99 percent of the patients said that 
they would call doctor for advice if side effects occur. Moreover, all patients said 
they would go to hospital for consulting with doctor. Nobody would stop taking 
ARVs or buy drugs from pharmacy to treat side effects.  
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Figure 3.8: Side effects that may happen during 
ART
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Table 3.7: Measures to be taken when side effects happen 
 
Stop taking 
ARV by 
myself 
Buy drug from 
pharmacy to 
treat side 
effects 
Call doctor 
for advice 
Go to hospital 
for consulting 
with doctor 
Do not 
know 
Others 
N Valid 0 0 116 117 0 5 
 Missing 117 117 1 0 117 112 
 
Note: Missing numbers in this table are the numbers of patients who did not 
respond or choose the answers. 
3.2.2.6. What are the benefits of taking ARV regularly, continuously, and correctly? 
Table 3.8: Benefits of taking ARVs regularly, continuously, and correctly 
 
Suppression 
of HIV viral 
load in blood 
Avoidance of 
resistance of 
HIV to ART 
Achievement 
of ART 
success 
Do not 
know 
Others 
N Valid 115 115 115 1 30 
Missing 2 2 2 116 87 
Note: Missing numbers in this table are the numbers of patients who did not 
respond or choose the answers. 
Table 3.8 shows that almost all patients (98 percent) knew the benefits of 
taking ARVs regularly, continuously, and correctly very well, saying that they take 
ARV to suppress HIV viral load in blood and to avoid resistance of HIV to ART or to 
achieve ART success. The remaining 30 out of the 117 patients provided other 
possible answers. 13 out of the 30 patients said that the benefits of taking ARVs 
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regularly, continuously, and correctly were good health, followed by nine high CD4, 
and eight prolonged life, prevention of opportunistic infections, HIV transmission, 
and reduction of HIV viral load in blood. 
After summing up all knowledge scores of the total six questions above, the 
author is able to calculate and assess the patients’ knowledge scores as in the table 
below.  
 3.2.2.7. Levels of ART knowledge 
Figure 3.9: Levels of ART knowledge of research participants 
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This pie chart reveals that almost all (89.7%) of the total research participants 
had high knowledge of ART, whereas the remaining 10.3 percent represented low 
knowledge of ART. Even though patients had a high level of ART knowledge, some 
of them still showed poor adherence to ART. 
3.2.3. Treatment regimens and OI treatments of the research participants 
 3.2.3.1. ART regimens 
The quality of life of the HIV/AIDS patients cannot be improved unless they 
take Antiretroviral drugs (ARV) appropriately and correctly. At Sihanouk Hospital 
Center of HOPE (SHCH), there are two kinds of ART regimens (Sihanouk Hospital 
Center of HOPE, 2008). The first regimen is first-line ART and the second regimen is 
second-line ART. Patients are provided first with the first-line ART, while the 
second-line ART is indicated when the HIV is resistant to the first-line ART or in 
case of first-line ART failure. In addition, second-line ART has higher pill burden 
than that of first-line ART and its cost is around 10 times higher than that of first-line 
ART.  
What ART drugs are you currently on? 
In table 3.9, there are two ART lines. First-line ART contains seven ART 
regimens such as 3TC+EFV+AZT, 3TC+EFV+TDF, 3TC+NVP+AZT, 
3TC+NVP+TDF, ABC+3TC+EFV, D4T+3TC+EFV, and D4T+3TC+NVP, while 
second-line ART has 4 ART regimens such as 3TC+TDF+KALETRA, 
3TC+TDF+KALETRA+AZT, ABC+DDI+KALETRA, and D4T+3TC+KALETRA. 
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Almost all of the HIV/AIDS patients (90 percent) were on the first-line ART, 
while the second-line ART accounted for only 10 percent. 3TC+NVP+AZT, 
D4T+3TC+NVP, and D4T+3TC+EFV regimens accounted for 35, 21, and 14 percent 
respectively, whereas the remaining ART regimens represented very low percentages.  
 
Table 3.9: ART regimens 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 3TC+EFV+AZT 11 9.4 9.4 9.4 
3TC+EFV+TDF 4 3.4 3.4 12.8 
3TC+NVP+AZT 41 35.0 35.0 47.9 
3TC+NVP+TDF 7 6.0 6.0 53.8 
3TC+TDF+KALETRA 4 3.4 3.4 57.3 
3TC+TDF+KALETRA+AZT 4 3.4 3.4 60.7 
ABC+3TC+EFV 1 .9 .9 61.5 
ABC+DDI+KALETRA 1 .9 .9 62.4 
D4T+3TC+EFV 17 14.5 14.5 76.9 
D4T+3TC+KALETRA 2 1.7 1.7 78.6 
D4T+3TC+NVP 25 21.4 21.4 100.0 
Total 117 100.0 100.0  
3.2.3.2. OI drug treatments 
Opportunistic Infection (OI) drugs are medicines other than ART drugs used 
by the HIV/AIDS patients to treat opportunistic infections such as tuberculosis, 
pneumonia, diarrhea, skin diseases, sexually transmitted diseases, meningitis, heart 
diseases, liver diseases, kidney diseases, and other opportunistic diseases that might 
occur in the patients. Moreover, drugs that are used to prevent the occurring of 
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opportunistic infections, for example, fungal infections and Pneumocystis Carinii 
Pneumonia (PCP), severe disease of lungs, also represent OI drugs. 
What other drugs (beside antiretroviral) are you currently on? 
3.2.3.2.1. OI drug use 
Figure 3.10: OI Drug use of research participants
 
Figure 3.10 illustrates that most all of the patients (87 percent) took 
opportunistic infection drugs, while the rest, 13 percent, did not take the medicines. 
HIV/AIDS patients used OI drugs because they had opportunistic infections and were 
not healthy.   
Figure 3.11 shows that pain killers were the medicine that the majority of the 
HIV/AIDS patients (67.5 percent) were taking to relieve their pains; appetite 
stimulants/vitamins were also popular among the patients with 52 percent of the 
patients taking them. Antibiotics, TB drugs, sleeping pills, and fluconazole 
prophylaxis were taken by a small number of the patients, with less than 10 percent of 
the patients taking them. Patients took the two most popular OI drugs, pain killers and 
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vitamins, because they had severe OIs and weak physical conditions. Therefore, they 
needed to take these drugs in order to reduce their pains and strengthen their power. 
       
3.2.3.2.2. Number of times taking OI drugs 
Taking OI drugs more frequently might cause patients to take their ARVs 
irregularly or incorrectly. 
Number of times taking OI drugs was calculated according to the names of the 
drugs. For instance, one tablet of OI drug was considered as one time taking OI drug, 
two different OI drugs considered as two times, and three OI drugs as three times.  
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Figure 3.11: OI drugs taken
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Figure 3.12: Number of time taking OI drugs 
The graph shows that 4 and 5 times taking OI drugs accounted for the majority, 25 
and 23 percent, respectively, while 2 times and 6 times taking OI drugs represented 
the same percent, 14. Whereas 1 time and 3 times taking OI drugs accounted for 11 
and 9 percent, respectively. The remaining times taking OI drugs, however, showed 
the smallest percents. 
3.2.3.2.3. Number of types of OI drugs 
The more OI drugs the patients take, the more pill burdens they have. High 
pill burdens of OI medicines are more likely to cause patients not to adhere to ART 
adherence. Different names of OI drugs have different types. 
The figure 3.13 shows that HIV/AIDS patients taking 1 type and 2 types of OI 
drugs represented 32 and 35 percent, respectively, while taking 3 types accounted for 
14 percent. Not taking any OI drugs consisted of 13 percent, whereas the rest showed 
the smallest percents. 
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Figure 3.13: Number of OI drug types 
 
3.2.3.3. Difficulty taking ARVs while taking OI drugs 
Table 3.10: Difficulty taking ARVs 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Not taking OI drugs 15 12.8 12.8 12.8 
Difficulty 5 4.3 4.3 17.1 
No difficulty 97 82.9 82.9 100.0 
Total 117 100.0 100.0  
This table illustrates that among the total 117 research respondents, 13 percent 
did not take OI drugs. Most of the patients, 102 (87 percent) took OI drugs; however, 
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83 percent of them had no difficulty taking ARVs while using OI drugs. This 
indicates that taking OI drugs did not cause any problems of taking ART at all. The 
main reasons for not having difficulty taking tablets were that patients took ARVs 
and OI drugs separately, at different times; also, they had high commitment of taking 
their medicines, through reminding of their family members, relatives as well as their 
neighbors; some ART drugs are combined into one tablet, and taking drugs is as their 
habits. Nevertheless, only a minority of the participants had difficulty taking their 
ARVs due to some reasons, namely too many pill burdens, many times of taking their 
medicines, and ART side effects, especially nausea and vomiting. 
3.2.4. Side effects of ART of research participants 
In the side effects section, the author asked three questions from participants 
in order to get information on side effects of ART and its related characteristics.  
While taking ARVs, HIV/AIDS patients may encounter intolerant or adverse 
effects of the ART. There are, in fact, two kinds of ART side effects, short-term and 
long-term after taking ARVs. Short–term side effects can occur within six months of 
taking ARVs, including headache, nausea, vomiting, abdominal pain, nightmare, skin 
rash, diarrhea, liver toxicity, and others. While long-term side effects may happen 
while taking ARVs for at least six months; the long-term side effects are numbness of 
limbs, lipodystrophy, pancreatitis, anemia, and change in nail color. Side effects 
might influence adherence to ART. 
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3.2.4.1. Did you experience drug side effects? 
Figure 3.14: Patients’ experience of ART side effects 
 
This pie chart shows that the majority of all 117 research respondents (71 
percent) experienced side effects, while 29 percent did not experience side effects of 
ART. After taking ARVs, some HIV/AIDS patients might encounter side effects, of 
which some are minor; however, some are more serious and even deadly. 
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3.2.4.2. What are the side effects that you experienced? 
Figure 3.15: ART side effects that patients experienced 
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This graph reveals that among the 83 patients who experienced side effect, 
lipodystrophy was the leading side effect (41 percent), followed by gastro-intestinal 
and skin rash side effects, with the same percent, 14. Other side effects, 17 percent, 
were leg numbness, toxicity of nervous system, high fever, blurred vision, and even 
blindness. The rest, however, was the minority.  
3.2.4.3. Did side effects cause you to stop taking the medicine? 
Figure 3.16: Stop and no stop taking ART 
 
This pie chart illustrates that side effects were subjectively not a major barrier 
to taking ART drugs. Of those 82 patients who said they experienced side effects, 
only about 13 percent said side effects caused them to stop taking the medicines, 
Stop
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while 87 percent said the side effects did not stop them from taking the medicine. 
Even though the research respondents mentioned that side effects did not cause them 
to stop taking their ARVs, it is not sure whether it is the case or not. Therefore, a 
statistical analysis is needed in order to prove it.  
3.2.5. Reasons reported for missing ART doses in this study 
 
3.2.5.1. Did you take ARVs regularly and correctly? 
Table 3.11: Taking ARVs regularly, continuously, and correctly 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid Yes 55 47.0 47.0 47.0 
  No 62 53.0 53.0 100.0 
  Total 117 100.0 100.0  
The majority of the surveyed patients (53%) did not take ARVs regularly and 
correctly while 47 % said they did. 
 3.2.5.2. What are the factors that help you take ARVs regularly and correctly? 
 Most of the patients said alarm clock helped them take ARVs regularly and correctly. 
3.2.5.3. What cause you not to take your tablets? 
This question was asked to patients who had poor adherence to ART to seek 
for reasons that caused patients not to take their medicines generally. 
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This figure shows that one of the major causes of not taking tablets was 
forgetting (22.2%) to take ART tablets. Only six percent of the patients said that 
feeling very ill was the cause of not taking their tablets. The same percentage said 
fear of stigma/disclosure was also the cause. It is understood that most of the patients 
had enough stock of tablets to take. Only 1.7 percent said finished stock was the 
cause of not taking their tablets. The remaining 35.9 percent of reasons for not taking 
their ARVs were mostly due to being busy with their works, followed by conflicts 
with their family members as well as neighbors, taking care of their children, lack of 
time reminders such as cell phones and alarm clocks. 
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Figure 3.17: Causes not to take ARVs
96 
 
3.2.5.4. Many people find it hard to remember to take every single dose; in the last 
one month, how many doses have you missed? 
This question was asked to the patients to investigate whether the patients 
missed their ART doses one month prior to the interviews or not. By doing this, 
adherence to ART was found. In addition, one tablet of each ART drug means one 
dose; having failed to take one tablet means missing one dose of ART. Furthermore, 
missing ART more than three doses per month represents poor adherence to ART. 
       Figure 3.18: Status of ARV doses in the last month prior to interviews 
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This pie chart shows that the majority of the research respondents, 106 
(90.6%) out of the 117 patients did not miss their ART doses. Nevertheless, only 11 
(9.4%) of the patients missed their ART doses. Note that the patients subjectively 
provided the answers.  
 3.2.5.5. ARV drugs and its doses missed one month prior to interviews 
  Table 3.12: ARV drugs and its doses missed one month prior to interviews 
Patient D4T 3TC EFV NVP TDF KALETRA AZT 
1 1 1 
     2 1 1 
 
1 
   3 1 1 
 
1 
   4 
 
2 1 
 
1 
  5 2 2 
 
2 
   6 4 4 
     7 6 6 3 
    8 5 5 
   
10 
 9 
 
20 10 
   
20 
10 28 28 14 
    11 120 120 
 
120 
    
This table demonstrates that 11 (9.4%) out of 117 patients missed their ART 
doses one month prior to the interview. Each patient missed at least two doses of 
ART, for example, patient number 1 missed two doses, which was calculated by 
adding one dose of D4T to another dose of 3TC. Remarkably, patient number 9, 10, 
and number 11 each had missed 50 doses, 70 doses, and 360 doses of ART, 
respectively. Family conflicts; natural disasters, such as floods, which cut off the 
roads; and lack of money for transportation fees, were the causes of failing to take 
their ART doses. Patient number 11 had exclusively missed her ART doses because 
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of prolonging her stay to another two months in the United States. Eight (about 73%) 
out of 11 patients missed their ARVs more than three doses one month before the 
interview. This means that about 73% of 11 respondents who missed their medication 
doses were poor ART adherent patients (missed more than three doses in the last 
month prior to the interview) or eight (about 7%) of 117 were poor ART adherent 
patients. Therefore, poor ART adherence still exists. 
3.3. Results of association between dependent and independent variable analysis 
This section is divided into two parts. The first part is hypothesis testing such 
as drug side effects versus adherence to ART, ART regimens versus adherence to 
ART, OI drug uses versus adherence to ART, knowledge of HIV/AIDS patients on 
ART versus adherence to ART, educational levels versus adherence to ART, patient’s 
location of residence versus adherence to ART, and poverty versus adherence to 
ART. The second part is other socio-demographic and economic factors and 
adherence to ART testing such as WHO stages versus adherence to ART, CD4 
groups versus adherence to ART, sex versus adherence to ART, age groups versus 
adherence to ART, marital status versus adherence to ART, occupation versus 
adherence to ART, and food versus adherence to ART. 
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3.3.1. Hypothesis testing 
3.3.1.1. Results of association between side effects of ART and adherence to ART 
analysis 
Based on two kinds of adherence status of the respondents, poor and good 
adherent patients to ART, this section was divided into two parts: side effects versus 
adherence status cross-tabulation, and the statistical test, Chi-square to show whether 
there is any statistically significant association between side effects and adherence 
status or not. Cross-tabulations were performed only with hypothesis testing. 
3.3.1.1.1. ART side effects versus adherence status cross tabulation 
 
Table 3.13: Side effects versus adherence status cross-tabulation 
 
Adherence 
status 
Total Poor Good 
Side 
effects 
Experience ART side 
effects 
Count 36 47 83 
% within Side effects 43.4% 56.6% 100.0% 
% within Adherence 
status 
60.0% 82.5% 70.9% 
% of Total 30.8% 40.2% 70.9% 
No experience ART 
side effects 
Count 24 10 34 
% within Side effects 70.6% 29.4% 100.0% 
% within Adherence 
status 
40.0% 17.5% 29.1% 
% of Total 20.5% 8.5% 29.1% 
Total Count 60 57 117 
% within Side effects 51.3% 48.7% 100.0% 
% within Adherence 
status 
100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
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This table shows that the data classify 117 research respondents by side 
effects (experience side effects /no experience side effects) and adherence status 
(poor/good). The author ran the cross-tabulation procedure with side effects as the 
row variable and adherence status as the column variable. 
The top number in each cell is the count. The cell counts indicate that 36 poor 
adherent and 47 good adherent patients experienced side effects of ART; 24 poor 
adherent and 10 good adherent patients did not experience side effects of ART. 
Furthermore, the marginal counts indicate that 83 and 34 patients experienced and did 
not experience side effects, respectively and that there were 60 and 57 poor and good 
adherent patients, respectively. The total number of cases in the table is 117, which 
appears on the bottom-right hand corner of the table. 
The marginal percentages represent the percentage of the total that is found in 
the row or column. For instance, of the entire sample of 117 patients, 83 of them 
(70.9%) experienced side effects, while 34 (29.1%) of them did not experience side 
effects. Moreover, 51.3% of all of the patients were poor adherent patients, while 
48.7% were good adherent patients. 
Below the count is the % within side effects or the row percentage, which 
represents the percentage of the row that is found in the cell. For example, 43.4% of 
all patients who experienced side effects were poor adherent patients, while 56.6% 
were good adherent patients. 
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While the third number, % within adherence status, in each cell is the column 
percentage or percentage of poor or good adherent patients, who experienced or did 
not experience side effects. Taken as an example, 60.0% of the 60 poor adherent 
patients experienced side effects, however, 40.0% did not experience side effects. In 
addition, 82.5% of the 57good adherent patients experienced side effects, while 
17.5% of them did not experience side effects. 
The last line of each cell, labeled % of total, indicates the total percentage. 36 
poor adherent patients, who experienced drug side effects, represented 30.8% of all 
117 patients, while 24 (20.5%) were poor adherent patients who did not have 
experience of drug side effects. In addition, 40.2% of the total sample were good 
adherent patients who experienced side effects, while 8.5% were good adherent 
patients who did not experience side effects. 
Although there were different percentages between poor adherent patients 
(43.4%) and good adherent patients (56.6%) of the total 83 patients who experienced 
side effects, in this small sample there is probably a weak strength of association 
between drug side effects and adherence to ART. Therefore, a statistical significance 
test such as Chi-square is needed to measure the strength of association between 
dependent variable (adherence status) and independent variable (side effects). 
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3.3.1.1.2. Chi-square test for association between ART side effects and adherence to 
ART 
Table 3.14: Chi-square test for association between ART side effects and adherence to 
ART 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 7.150
a
 1 .007   
Continuity Correction 6.102 1 .013   
Likelihood Ratio 7.325 1 .007   
Fisher's Exact Test    .009 .006 
Linear-by-Linear 
Association 
7.089 1 .008 
  
N of Valid Cases 117     
 
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 16.56. 
b. Computed only for a 2x2 table 
3.3.1.1.3. Chi-square test for association between gastro-intestinal side effects and 
adherence to ART Analysis 
Table 3.15: Chi-square test for association between gastro-intestinal side effects 
and adherence to ART 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-Square 9.535
a
 1 .002   
Continuity Correction 7.916 1 .005   
Likelihood Ratio 9.712 1 .002   
Fisher's Exact Test    .003 .002 
Linear-by-Linear 
Association 
9.420 1 .002 
  
N of Valid Cases 83     
 
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.37. 
b. Computed only for a 2x2 table 
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Table 3.14 shows that there was a statistically significant association between 
drug side effects and adherence to ART (X²=7.150, df =1, P-value (Asymp 
Sig.)=0.007).  
Table 3.15 demonstrates that, of all the side effects that patients experienced, 
only gastro-intestinal side effects such as nausea, vomiting, and abdominal pain are 
statistically significantly associated with adherence to ART (X²= 9.535, df= 1, P-
value= 0.002). 
3.3.1.2. Results of association between treatment ART regimens and adherence to 
ART of the research participants 
3.3.1.2.1. ART regimens versus adherence status cross-tabulation 
At Sihanouk Hospital Center of HOPE (SHCH) and in Cambodia, there are 
only two ART line regimens, first-line and second-line ART regimens. First-line 
ART regimen consists of seven regimens such as 3TC+EFV+AZT , 3TC+EFV+TDF, 
3TC+NVP+AZT, 3TC+NVP+TDF, ABC+3TC+EFV, D4T+3TC+EFV, and   
D4T+3TC+NVP, while second-line ART regimen is composed of four regimens such 
as 3TC+TDF+KALETRA, 3TC+TDF+KALETRA+AZT, ABC+DDI+KALETRA, 
and D4T+3TC+KALETRA. 
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Table 3.16: ART regimens versus adherence status cross-tabulation 
 
 
Adherence status 
Total 
Poor Good 
ART regimens First-line 
ART 
regimens 
Count 55 51 106 
% within ART regimens 51.9% 48.1% 100.0% 
% within Adherence status 91.7% 89.5% 90.6% 
% of Total 47.0% 43.6% 90.6% 
Second- 
line ART 
regimens 
Count 5 6 11 
% within ART regimens 45.5% 54.5% 100.0% 
% within Adherence status 8.3% 10.5% 9.4% 
% of Total 4.3% 5.1% 9.4% 
                Total Count 60 57 117 
% within ART regimens 51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
 
 This table illustrates that almost all patients, 106 (90.6%) of the total 117 
patients, were on first-line ART regimens, while 11 (9.4%) patients were on second- 
line ART regimens. Among 106 patients who were on first-line ART, 55 and 51 
patients belonged to poor adherent and good adherent patient groups, respectively. 
Among 11 patients who were on second-line ART, five and six patients belonged to 
poor adherent and good adherent patients, respectively. Furthermore, there is not a 
big difference between poor adherent and good adherent patients who use first-line 
ART regimens. Similarly, there is also not a big difference between poor adherent 
and good adherent patients who were on second-line ART regimens. Based on this 
context, statistical test, Chi-square is needed in order to make sure whether there is 
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any statistically significant association between ART drug regimens and adherence to 
ART or not. 
3.3.1.2.2. Chi-square test for association between ART regimens and adherence to 
ART 
After running a Chi-square test in the SPSS version 18, the result shows that 
there was no statistically significant association between ART regimens and 
adherence to ART (X²= 0.165, df= 1, P-value= 0.685). 
3.3.1.3. Results of association between OI Drug uses and adherence to ART analysis 
3.3.1.3.1. OI drug uses versus adherence status cross-tabulation 
The table 3.17 shows that the majority of the patients, 102 (87.2%) of the 
entire 117 sample, used OI drugs, while only 15 (12.8%) did not use them. As can be 
seen in the table, the number of poor adherent patients (52) and good adherent 
patients (50) who used OI drugs is similar. Also, there is almost the same number of 
poor adherent and good adherent patients who did not use OI drugs. In addition, it is 
not sure whether any association between OI drug uses and adherence to ART exists 
or not. Therefore, a statistical test is needed for evidence. 
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Table 3.17: OI drug use of patients versus adherence status cross-tabulation 
 
 
Adherence status 
Total 
Poor Good 
OI drug use 
of patients 
Use drugs Count 52 50 102 
% within OI drug use of 
patients 
51.0% 49.0% 100.0% 
% within Adherence status 86.7% 87.7% 87.2% 
% of Total 44.4% 42.7% 87.2% 
No use Count 8 7 15 
% within OI drug use of 
patients 
53.3% 46.7% 100.0% 
% within Adherence status 13.3% 12.3% 12.8% 
% of Total 6.8% 6.0% 12.8% 
Total Count 60 57 117 
% within OI drug use of 
patients 
51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
 
3.3.1.3.2. Chi-square test for association between OI drug uses and adherence to ART 
analysis 
The Chi-square test result shows that there is no statistically significant 
association between OI drug uses and adherence to ART because of (X²= 0.29, df= 1, 
P value= 0.865). 
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3.3.1.4. Results of association between knowledge levels of HIV/AIDS patients of ART 
and adherence to ART analysis 
3.3.1.4.1. ART knowledge levels versus adherence status cross-tabulation 
ART knowledge levels were divided into two groups, high knowledge level 
and low knowledge level. High ART knowledge level was defined with the answer 
score higher than or equal to 15, while low ART knowledge level with the answer 
score lower than or equal to 14, and the maximum accurate answer score was 16. 
Table 3.18: ART knowledge levels versus adherence status cross-tabulation 
 
 
Adherence status 
Total 
Poor Good 
ART knowledge High 
knowledge 
Count 54 51 105 
% within ART 
knowledge 
51.4% 48.6% 100.0% 
% within Adherence 
status 
90.0% 89.5% 89.7% 
% of Total 46.2% 43.6% 89.7% 
Low 
knowledge 
Count 6 6 12 
% within ART 
knowledge 
50.0% 50.0% 100.0% 
% within Adherence 
status 
10.0% 10.5% 10.3% 
% of Total 5.1% 5.1% 10.3% 
Total Count 60 57 117 
% within ART 
knowledge 
51.3% 48.7% 100.0% 
% within Adherence 
status 
100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
 
This table demonstrates that the majority, 105 (89.7%) of the total 117 
respondents had a high knowledge level, while only 12 (10.3%) had a low knowledge 
level of ART. However, there was no big difference between poor and good adherent 
patients, who had a high knowledge level. Furthermore, the number of poor and good 
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adherent patients who had a low knowledge level of ART was the same. Therefore, it 
is unlikely that there is an association between knowledge of ART and adherence to 
ART. To identify if there is any association between ART knowledge and adherence 
or not, Chi-square test is necessary. 
3.3.1.4.2. Chi-square test for association between ART knowledge level and 
adherence to ART 
There is no statistically significant association found between ART 
knowledge and adherence to ART (X²= 0.009, df=1, P-value= 0.925). 
3.3.1.5. Results of association between educational levels and adherence to ART 
analysis 
3.3.1.5.1. Educational levels versus adherence status cross-tabulation 
       
            Table 3.19 illustrates that there are four levels of education such as illiterate, 
primary school, secondary school, as well as high school and university. 31 (26.5%), 
40 (34.2%), 27 (23.1%), and 19 (16.2%) of all the entire sample 117 patients 
represented illiterate, primary school, secondary school, and high school or 
university, respectively. Moreover, illiterate respondents mean that they cannot read, 
write, and understand Khmer language as their mother tongue. 26.5% illiterate among 
the 117 study participants are remarkably high. The number of patients, who had 
attended primary school, is the largest of all educational levels, 34.2%. As can be 
seen in the table, except for primary school, the higher the levels of education, the 
lower the numbers they are. There 19 poor adherent patients out of 31 who are 
illiterate, while good adherent patients accounted for only 12. Similarly, the numbers 
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of poor and good adherent patients in primary school and secondary school levels of 
education are not so different. Noticeably, among the 19 research participants who 
had attended high school or university, there were seven poor adherent patients, while 
good adherent patients accounted for 12, which is nearly double the number of poor 
adherent patients. Although there is not a big difference between the numbers of poor 
and good adherent patients in each level of education, except for high school or 
university level, it is necessary to have a significance test to measure if any 
association between educational levels and adherence to ART exists or not. 
         Table 3.19: Education revels versus adherence status cross-tabulation 
  
Adherence status 
Total Poor Good 
Educational 
levels 
Illiterate Count 19 12 31 
% within Educational levels 61.3% 38.7% 100.0% 
% within Adherence status 31.7% 21.1% 26.5% 
% of Total 16.2% 10.3% 26.5% 
Primary 
school 
Count 22 18 40 
% within Educational levels 55.0% 45.0% 100.0% 
% within Adherence status 36.7% 31.6% 34.2% 
% of Total 18.8% 15.4% 34.2% 
Secondary 
school 
Count 12 15 27 
% within Educational levels 44.4% 55.6% 100.0% 
% within Adherence status 20.0% 26.3% 23.1% 
% of Total 10.3% 12.8% 23.1% 
High school 
or university 
Count 7 12 19 
% within Educational levels 36.8% 63.2% 100.0% 
% within Adherence status 11.7% 21.1% 16.2% 
% of Total 6.0% 10.3% 16.2% 
Total Count 60 57 117 
% within Educational levels 51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
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3.3.1.5.2. Chi-square test for association between educational levels and adherence to 
ART 
There is no statistically significant association between education of research 
participants and ART adherence because (X²= 3.555, df= 3, P-value= 0.314). 
3.3.1.6. Results of association between patient’s location of residence and adherence 
to ART analysis 
               Patient’s location of residence was divided into two categories, Phnom Penh 
and provinces. Phnom Penh is the capital city of Cambodia, which is defined as 
within about 30 km from the research study, Sihanouk Hospital Center of HOPE, 
while provinces are at least farther than 30 km away from the research study. 
3.3.1.6.1. Patient’s location of residence versus adherence status cross-tabulation 
            Table 3.20 indicates that most of the 117 study participants, 73 (62.4%) lived 
in Phnom Penh, while 44 (37.6%) lived in provinces. However, the numbers of poor 
and good adherent patients, who lived in Phnom Penh, were almost the same. Of the 
44 patients who lived in provinces, the numbers of poor and good adherent patients 
were nearly the same, too. Since there was almost no difference between the numbers 
of poor and good adherent patients living in Phnom Penh and provinces, it is unlikely 
that an association between patient’s location of residence and adherence to ART 
exists. In order to respond to this context, Chi-square test is in need for confirming 
the association.  
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Table 3.20: Patient’s location of residence versus adherence status Cross-
tabulation 
 
Adherence status 
Total 
Poor Good 
Patient’s 
location 
of 
residence 
 Phnom  
Penh 
Count 37 36 73 
% within Patient’s location of 
residence 
50.7% 49.3% 100.0% 
% within Adherence status 61.7% 63.2% 62.4% 
% of Total 31.6% 30.8% 62.4% 
Provinces Count 23 21 44 
% within Patient’s location of 
residence 
52.3% 47.7% 100.0% 
% within Adherence status 38.3% 36.8% 37.6% 
% of Total 19.7% 17.9% 37.6% 
Total Count 60 57 117 
% within Patient’s location of 
residence 
51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
              
 3.3.1.6.2. Chi-square test for association between patient’s location of residence and 
adherence to ART. 
           There is no statistically significant association between patient’s location of 
residence and adherence to ART (X²=0.28, df=1, P-value= 0.868). 
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3.3.1.7. Results of association between poverty and adherence to ART analysis 
3.3.1.7.1. Economic status versus adherence status cross-tabulation 
           The economic status of the study respondents was classified into two levels, 
poor and not poor. Poor patients were defined with earning a money income less than 
or equal to 1US$ (1US$=4000 Riel, local currency) per day, while not poor patients 
with earning a money income more than 1US$ per day. 
           Table 3.21 shows that the majority of the total 117 participants, 82 (70.1%) 
were poor, while 35 (29.9%) were not poor patients. It is clear that among all 82 poor 
patients, the numbers of poor and good adherent patients were nearly the same, with 
42 and 40, respectively. Likewise, there were almost the same number of poor and 
good adherent patients who were not economically poor, 18 and 17, respectively. For 
that reason, a statistical test such us Chi-square is needed to confirm whether or not 
there is any association between poverty and adherence to ART. 
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Table 3.21: Economic status versus adherence status cross-tabulation 
 
Adherence status 
Total 
Poor Good 
Economic 
status 
   Poor  Count 42 40 82 
 % within Economic 
status 
51.2% 48.8% 100.0% 
 % within Adherence 
status 
70.0% 70.2% 70.1% 
 % of Total 35.9% 34.2% 70.1% 
Not       
poor 
Count 
18 17 35 
 % within Economic 
status 
51.4% 48.6% 100.0% 
 % within Adherence 
status 
30.0% 29.8% 29.9% 
% of Total 15.4% 14.5% 29.9% 
              Total Count 60 57 117 
 % within Economic 
status 
51.3% 48.7% 100.0% 
 % within Adherence 
status 
100.0% 100.0% 100.0% 
 % of Total 51.3% 48.7% 100.0% 
 
 
3.3.1.7.2. Chi-square test for association between poverty and adherence to ART 
          There is no any statistically significant association between poverty and 
adherence to ART (X²=0.000, df=1, P value=0.983). 
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3.3.2. Results of association between gender, age groups, CD4 groups, WHO stages, 
marital status, occupations, food access status and adherence to ART Analysis 
3.3.2.1. Results of association between gender and adherence to ART analysis 
 
Table 3.22: Gender versus adherence status cross-tabulation 
 
 Adherence status 
Total Poor Good 
Gender Male Count 26 19 45 
% within Gender 57.8% 42.2% 100.0% 
% within Adherence status 43.3% 33.3% 38.5% 
% of Total 22.2% 16.2% 38.5% 
Female Count 34 38 72 
% within Gender 47.2% 52.8% 100.0% 
% within Adherence status 56.7% 66.7% 61.5% 
% of Total 29.1% 32.5% 61.5% 
Total Count 60 57 117 
% within Gender 51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
 
          This table indicates that the majority of the research respondents, 72 (61.5%) 
were females. However, the number of poor and good adherent patients of the total 
females was not so different, while the number of males accounted for 45 (38.5%) of 
the entire 117 sample. Also, among the 45 males, the number of poor and good 
adherent patients was 26 and 19, respectively. There was no statistically significant 
association between gender and adherence to ART (X²= 1.235, df= 1,                       
P-value=0.266). 
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3.3.2.2. Results of association between age groups and adherence to ART analysis 
        Table 3.23 shows that the number of poor and good adherent patients in the age 
groups 30-34 and 35-39 years old was almost the same. These two age groups had a 
greater number than that of the other age groups. Similarly, the number of the age 
groups 40-44 and older than 44 years old was nearly the same. However, the number 
of poor and good adherent patients in the age group 30-34 years old was nine and 14, 
respectively. Of the age group older than 44 years old, poor adherent patients 
accounted for 14, while good adherent patients were 10, which was slightly different. 
However, there is no statistically significant association between age groups and 
adherence to ART (X²= 2.315, df= 4, P-value= 0.678). 
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Table 3.23: Age groups  versus Adherence status Cross-tabulation 
 
Adherence status 
Total Poor Good 
Age groups Age group 
younger than 30 
years old 
Count 9 6 15 
% within Age groups 60.0% 40.0% 100.0% 
% within Adherence 
status 
15.0% 10.5% 12.8% 
% of Total 7.7% 5.1% 12.8% 
Age group 30-34 
years old 
Count 14 13 27 
% within Age groups 51.9% 48.1% 100.0% 
% within Adherence 
status 
23.3% 22.8% 23.1% 
% of Total 12.0% 11.1% 23.1% 
Age group 35-39 
years old 
Count 14 14 28 
% within Age groups 50.0% 50.0% 100.0% 
% within Adherence 
status 
23.3% 24.6% 23.9% 
% of Total 12.0% 12.0% 23.9% 
Age group 40-44 
years old 
Count 9 14 23 
% within Age groups 39.1% 60.9% 100.0% 
% within Adherence 
status 
15.0% 24.6% 19.7% 
% of Total 7.7% 12.0% 19.7% 
Age group older 
than 44 years old 
Count 14 10 24 
% within Age groups 58.3% 41.7% 100.0% 
% within Adherence 
status 
23.3% 17.5% 20.5% 
% of Total 12.0% 8.5% 20.5% 
Total Count 60 57 117 
% within Age groups 51.3% 48.7% 100.0% 
% within Adherence 
status 
100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
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3.3.2.3. Results of association between CD4 groups and adherence to ART 
analysis 
           Table 3.24: CD4 groups versus adherence status cross-tabulation 
 
Adherence status 
Total 
Poor Good 
CD4 
groups 
CD4 group1-99   Count 33 33 66 
   % within CD4 groups 50.0% 50.0% 100.0% 
   % within Adherence status 55.0% 57.9% 56.4% 
   % of Total 28.2% 28.2% 56.4% 
CD4 group 
100-199     
   Count 11 11 22 
   % within CD4 groups 50.0% 50.0% 100.0% 
   % within Adherence status 18.3% 19.3% 18.8% 
   % of Total 9.4% 9.4% 18.8% 
CD4 greater 
than 199 
   Count 16 13 29 
   % within CD4 groups 55.2% 44.8% 100.0% 
   % within Adherence status 26.7% 22.8% 24.8% 
   % of Total 13.7% 11.1% 24.8% 
Total    Count 60 57 117 
   % within CD4 groups 51.3% 48.7% 100.0% 
   % within Adherence status 100.0% 100.0% 100.0% 
   % of Total 51.3% 48.7% 100.0% 
 
          This table demonstrates that the majority of all the research respondents, 56.4 
percent, had CD4 group 1-99. Poor and good adherent patients, nonetheless, 
accounted for the same number, 33. Likewise, of the 29 patients, who have CD4 
group greater than 199, the number of poor and good adherent patients was almost 
the same. In this context, no statistically significant association between CD4 groups 
and adherence to ART was found at all (X²=0.234, df= 2, P-value= 0.890). 
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3.3.2.4. Results of association between WHO stages and adherence to ART analysis 
Table 3.25: WHO stage versus adherence status cross-tabulation 
 
Adherence status 
Total 
Poor Good 
WHO 
stage 
WHO 
stage 1 
Count 6 1 7 
% within WHO stage 85.7% 14.3% 100.0% 
% within Adherence status 10.0% 1.8% 6.0% 
% of Total 5.1% .9% 6.0% 
WHO 
stage 2 
Count 9 8 17 
% within WHO stage 52.9% 47.1% 100.0% 
% within Adherence status 15.0% 14.0% 14.5% 
% of Total 7.7% 6.8% 14.5% 
WHO 
stage 3 
Count 24 28 52 
% within WHO stage 46.2% 53.8% 100.0% 
% within Adherence status 40.0% 49.1% 44.4% 
% of Total 20.5% 23.9% 44.4% 
WHO 
stage 4 
Count 21 20 41 
% within WHO stage 51.2% 48.8% 100.0% 
% within Adherence status 35.0% 35.1% 35.0% 
% of Total 17.9% 17.1% 35.0% 
Total Count 60 57 117 
% within WHO stage 51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
 
            This table illustrates that the number of HIV/AIDS patients with WHO stages 
3 and 4 was 44.4 and 35 percent, respectively. Of the WHO stage 4 subjects, poor 
and good adherent patients accounted for nearly the same. The number of poor and 
good adherent patients in WHO stage 3 was slightly different. Even so, there is no 
statistically significant association between WHO stages and adherence to ART (X²= 
3.888, df= 3, P-value= 0.274). 
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3.3.2.5. Results of Association between Marital Status and Adherence to ART 
Analysis 
Table 3.26: Marital status versus adherence status cross-tabulation 
 
Adherence status 
Total 
Poor Good 
Marital status Single Count 3 5 8 
% within Marital status 37.5% 62.5% 100.0% 
% within Adherence status 5.0% 8.8% 6.8% 
% of Total 2.6% 4.3% 6.8% 
Married Count 37 32 69 
% within Marital status 53.6% 46.4% 100.0% 
% within Adherence status 61.7% 56.1% 59.0% 
% of Total 31.6% 27.4% 59.0% 
Divorced Count 13 11 24 
% within Marital status 54.2% 45.8% 100.0% 
% within Adherence status 21.7% 19.3% 20.5% 
% of Total 11.1% 9.4% 20.5% 
Others Count 7 9 16 
% within Marital status 43.8% 56.3% 100.0% 
% within Adherence status 11.7% 15.8% 13.7% 
% of Total 6.0% 7.7% 13.7% 
                 Total Count 60 57 117 
% within Marital status 51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
 
 
           This table shows that the majority of all research respondents (59 percent) 
were married. However, there was not a big difference between numbers of poor and 
good adherent patients. Among the 24 patients who were divorced, the number of 
poor adherent and good adherent patients was similar. In addition, there is no 
statistically significant association between marital status and adherence to ART 
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(X²= 5.289, df= 5, P-value= 0.382). 
3.3.2.6. Results of association between occupation and adherence to ART Analysis 
Table 3.27: Occupation versus adherence status cross-tabulation 
 
Adherence status 
Total 
Poor Good 
Occupations    Unemployed Count 12 15 27 
% within Occupation 44.4% 55.6% 100.0% 
% within Adherence status 20.0% 26.3% 23.1% 
% of Total 10.3% 12.8% 23.1% 
Farmer Count 5 2 7 
% within Occupation 71.4% 28.6% 100.0% 
% within Adherence status 8.3% 3.5% 6.0% 
% of Total 4.3% 1.7% 6.0% 
Civil servant Count 3 10 13 
% within Occupation 23.1% 76.9% 100.0% 
% within Adherence status 5.0% 17.5% 11.1% 
% of Total 2.6% 8.5% 11.1% 
Small 
business/self 
employed 
Count 16 15 31 
% within Occupation 51.6% 48.4% 100.0% 
% within Adherence status 26.7% 26.3% 26.5% 
% of Total 13.7% 12.8% 26.5% 
Company 
worker 
Count 17 8 25 
% within Occupation 68.0% 32.0% 100.0% 
% within Adherence status 28.3% 14.0% 21.4% 
% of Total 14.5% 6.8% 21.4% 
Others Count 7 7 14 
% within Occupation 50.0% 50.0% 100.0% 
% within Adherence status 11.7% 12.3% 12.0% 
% of Total 6.0% 6.0% 12.0% 
       Total Count 60 57 117 
% within Occupation 51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
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             This table shows that the number of small business/self-employed patients is 
greater than that of the other occupations. Of the 31 (26.5%), however, the number of 
poor and good adherent patients was almost the same, 16 versus 15. Among the 25 
patients who are unemployed, 12 were poor adherent and 15 good adherent patients. 
Moreover, company workers, third range from small business/self-employed patients, 
accounted for 25, of whom 17 were poor adherent, while eight were good adherent 
patients. As can be seen in the table, there is a big difference between the numbers of 
poor and good adherent patients in the company worker occupation. Farmers, in 
contrast, have the smallest number among all the occupations. Though there are some 
similarities and differences between the numbers of poor and good adherent patients, 
there is no statistically significant association between occupations and adherence to 
ART (X²= 8.589, df= 5, P-value= 0.127). 
3.3.2.7. Results of association between food and adherence to ART analysis 
             Table 3.28 demonstrates that 60 (51.3%) and 57 (48.7%) of the entire 117 
sample, were poor and good adherent patients, respectively. The majority of all the 
research respondents, 68 (58.1%) had enough food to eat every day, while 49 
(49.1%) did not have it. Although about 49 percent of all the patients who 
participated in the study did not have enough food to eat every day, this number is 
higher than the poverty rate in Cambodia, which is about 35 percent of the total 
population. Even though a difference between enough and not enough food to eat 
daily is found, there is no statistically significant association between food and 
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adherence to ART (X²= 0.179, df= 1, P-value= 0.672). 
         Table 3.28: Food status versus adherence status cross-tabulation 
 
Adherence status 
Total Poor Good 
Food 
status 
Enough Count 36 32 68 
% within Food status 52.9% 47.1% 100.0% 
% within Adherence status 60.0% 56.1% 58.1% 
% of Total 30.8% 27.4% 58.1% 
Not 
enough 
Count 24 25 49 
% within Food status 49.0% 51.0% 100.0% 
% within Adherence status 40.0% 43.9% 41.9% 
% of Total 20.5% 21.4% 41.9% 
Total Count 60 57 117 
% within Food status 51.3% 48.7% 100.0% 
% within Adherence status 100.0% 100.0% 100.0% 
% of Total 51.3% 48.7% 100.0% 
 
3.4. Chapter summary 
             The results presented above indicate clearly that there are 60 and 57 poor and 
good adherent patients out of the entire sample 117, and most of the study subjects 
experienced side effects of ART. The study focuses on looking for barriers to 
antiretroviral therapy adherence of HIV/AIDS patients at Sihanouk Hospital Center 
of HOPE, Phnom Penh, Cambodia.  
            Table 3.29 presents the results of association between socio-demographic and 
economic factors other than those included in the hypothesis testing and adherence to 
ART analyses. There are four columns in the table; the first represents variables of 
study, second Chi-square test values, third degree of freedom (DF), and last column 
P-value. As can be seen in the table, socio-demographic and economic factors such as 
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gender, age groups, and CD4 groups are not statistically significantly associated with 
adherence to ART since all the P-values are greater than 0.05 (α-level). 
Table 3.29: Summary of Chi-square test of association between socio-economic 
factors and adherence to ART 
Variables 
Chi-square 
value (X²) 
DF -value 
Gender vs adherence to ART 1.235 1 0.266 
Age groups vs adherence to ART 2.315 4 0.678 
CD4 groups vs adherence to ART 0.234 2 0.89 
WHO stages vs adherence to ART 3.888 3 0.274 
Marital status vs adherence to ART 5.289 5 0.382 
Occupations vs adherence to ART 8.589 5 0.127 
Food status vs adherence to ART 0.179 1 0.672 
 
 
Table 3.30 shows the results of hypothesis testing. This table has four 
columns, of which each represents the same elements as those of table 3.29. ART side 
effects are the only one out of the seven hypothesis testing variables that is 
statistically significantly associated with adherence to ART (P-value= 0.007). In 
addition, of all the side effects that most HIV/AIDS patients experienced, gastro-
intestinal side effects such as nausea, vomiting, and abdominal pain, are specifically 
the only ones which have a significant association with adherence to ART (P-value= 
0.002). 
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Table 3.30: Summary of Chi-square test of association of hypothesis testing 
Variables 
Chi-square 
value (X²) 
DF P-value 
ART regimens vs adherence to ART 0.165 1 0.685 
OI drug uses vs adherence to ART 0.29 1 0.865 
Knowledge of ART vs adherence to ART 0.009 1 0.925 
Educational levels vs adherence to ART 3.555 3 0.314 
Patient's address vs adherence to ART 0.28 1 0.868 
Poverty vs adherence to ART 0 1 0.983 
Side effects vs adherence to ART 7.15 1 0.007 
 
Gastro-intestinal side effects vs adherence 
to ART 
9.535 1 0.002 
Therefore, the barriers to antiretroviral therapy adherence of the HIV/AIDS 
patients are mainly the ART side effects of which only gastro-intestinal side effects 
are statistically significantly associated with poor ART adherence.  
A more detailed summary and discussions of the findings are presented in the 
next chapter.  
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CHAPTER IV: SUMMARY, DISCUSSIONS, CONCLUSIONS, POLICY 
IMPLICATIONS, AND SUGGESTION FOR FUTURE RESEARCH 
This chapter is divided into five sections. First, the summary section provides 
statement of research problems and reviews major methods used in this study. 
Second, the discussion section summarizes and compares findings with those of 
previous research in accordance with research objectives, research questions, and 
research hypotheses. Third, the conclusion section draws conclusions from discussion 
section and overall contents of the study in relation to research objectives. Fourth, the 
policy implication section provides comprehensive interventions and 
recommendations to stakeholders for improving ART adherence. Last, the suggestion 
for future research section seeks to fill up the gaps in the study. 
4.1. Summary 
Adherence to antiretroviral therapy is a global problem, especially in poor-
resource setting countries such Cambodia as an example. This study was conducted to 
identify barriers to antiretroviral therapy adherence of HIV/AIDS patients at 
Sihanouk Hospital Center of HOPE between August 16, 2010 and September 30, 
2010. The study design is a cross-sectional survey in the form of a case-control study 
of poor ART adherent patients and good ART adherent patients, which employed 
both quantitative and qualitative approaches. Purposive and simple random sampling 
techniques were used in the study for recruiting poor ART adherent patients and good 
ART adherent patients, respectively. 
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Primary data were collected using face-to-face interviews through a self-
administered and structured questionnaire. While secondary data were collected using 
cohort data in order to identify poor ART adherent patients and good ART adherent 
patients among all HIV/AIDS patients who were on highly active antiretroviral 
therapy (HARRT) through a visual analogue scale at the Infectious Disease 
Department of Sihanouk Hospital Center of HOPE. Also, the secondary data were 
collected through a variety of other sources in a bid to find out relevant documents, 
information, and previous research findings. 
In total, 117 subjects were recruited in the study, 60 of whom were poor ART 
adherent patients, and 57 good ART adherent patients. The author had a list of these 
poor and good ART adherent patients before the interviews. Furthermore, data were 
coded and analyzed using SPSS version 18, and Chi-square test was used to identify 
the association between dependent and independent categorical variables. Results of 
data analysis show that the majority (93%) of the total 117 research respondents are 
good ART adherent patients, while seven percent are poor ART adherent patients. 
4.2. Discussions 
The results of analysis were discussed following three main parts: results of 
reasons reported for missing ART doses in this study, results of hypothesis testing, 
and results of socio-demographic and economic factors.  
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4.2.1. Discussions on results of reasons reported for missing ART doses in this study 
When asked (do you take ARVs regularly, continuously, and correctly?), 47 
percent of all research subjects said that they took their ARVs correctly, while 53 
percent said that they took their ARVs incorrectly. This question was asked in order 
to know whether or not patients take ARVs correctly. The question did not focus on 
patients’ taking their ARVs in the last month before the interviews; however, it 
intended to get general information on ART adherence and seems to be true 
according to their answers since they have taken ARVs by the time of interviews. 
This result is similar to previous research findings (Paterson et al., 2002; World 
Health Organization, 2003; Steel, Nwokike & Joshi, 2007).  
Most of the patients who took ARVs correctly said that alarm clock, 
reminders of family, relatives, and friends, along with high commitment, were the 
key factors for taking ARVs correctly. These answers may be reasonable and 
acceptable in their daily routine and practice. They are also consistent with previous 
research findings (Machtinger & Bangsberg, 2006; Huong, 2009). Among those who 
took ARVs incorrectly, the reasons for missing medication doses were forgetfulness 
(22.2%), being busy, conflicts with family and neighbors, lacks of time reminders 
such as alarm clock and cell phone, which altogether contributed to 35.9%, too ill 
(6%), fear of stigma/disclosure (6%), drunk with alcohol (5.1%), felt better (2.6%), 
developed toxicity/side effects (2.6%), too many pills/pill burden (2.6%), or stock 
was finished (1.7%). These results are likely true and similar to previous research 
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findings (Hardon et al, 2006; Markos, Worku, & Davey, 2008; Wanjohi, 2009). 
Furthermore, when asked (many people find it hard to remember to take every single 
dose; how many doses of ARVs in the last month prior to interview have you 
missed?), the majority of research respondents 106 (90.6%) did not miss their doses, 
while 11 (9.4%) missed their doses. Eight (about 73%) of 11 respondents missed 
ART more than three doses during one month before the interview. This equaled 
about seven percent of all research respondents that are poor ART adherent patients. 
The percentage of poor ART adherent patients (about 7%) in this study is higher than 
the percentage of poor ART adherent patients (about 3%) of all 2467 HIV/AIDS 
patients who were on ART since the beginning of ART program until March 2010 at 
Sihanouk Hospital Center of HOPE. This finding seems to be true because when 
interviewing respondents, the author used the questionnaire, which was prepared and 
organized in detail in order to seek for answers and information in accordance with 
the study objectives. Another possibility is that patients so far might have over-
reported ART adherence to physicians and counselors fearing of being blamed by 
health care providers if they tell their real ART adherence. Therefore, most of the 
research respondents (93%) in this study are good ART adherent patients, while eight 
(7%) are poor ART adherent patients. The percentage of poor adherence in this study 
is much lower than that of some previous studies as follows: Ethiopia, 26% (Markos, 
Worku & Davey, 2008), Kenya, 26% (Wanjohi, 2009), and Vietnam, 37% (Huong, 
2009). Also, the percentage of poor ART adherent patients (7%) is lower than that in 
the national level (13%) (NAA, 2007) and even lower than the percentage of poor 
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ART adherent patients at Calmette Hospital (29%) (Olivier et al., 2010). This study 
has a lower level of poor ART adherence (7%) than that in other studies, possibly due 
to the fact that Sihanouk Hospital Center of HOPE provides free health care services 
to HIV/AIDS patients. Besides, health care staff of the hospital has probably the 
highest capacity of taking care, treatment, support, and management of HIV/AIDS 
patients in the country. 
4.2.2. Results of hypothesis testing 
There are seven hypotheses in this research:  
 ART side effects may influence adherence to ART. 
 ART regimens may influence adherence to ART. 
 Co-opportunistic infection treatment drugs may influence adherence to 
ART. 
 Levels of patient knowledge of ART may influence adherence to ART. 
 Educational levels of patients may influence adherence to ART. 
 Patient’s location of residence may influence adherence to ART 
 Poverty status of patients may influence adherence to ART. 
4.2.2.1. ART side effects may influence adherence to ART 
Results show that 83 (70.94%) of the total research respondents experienced 
side effects of which 43.4% were poor ART adherent patients. Among 34 patients 
who did not experience side effects, 24 (70.6%) were poor ART adherent patients.       
Out of 83 patients who experienced side effects, only about 13 percent experienced 
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adverse effects to the extent of stopping the medicines. However, the results of 
analysis show that ART side effects are statistically significantly associated with 
adherence to antiretroviral therapy (X²=7.150, df =1, P-value=0.007). It might be due 
to subjective answers of patients or patients might not know that these symptoms are 
ART side effects; or patients might have been accustomed to adverse effects of 
medications due to the physical and emotional morbidity or well-being related to 
patients. The significant association between ART side effects and adherence to 
antiretroviral therapy in this study is consistent with previous research findings 
(Ickovics & Meade, 2002; Castro 2005; Markos, Worku, & Davey, 2008; Cauldbeck, 
et al., 2009). Furthermore, in this study gastro-intestinal problems are the only one 
ART side effects that are statistically significantly associated with ART adherence 
(X²= 9.535, df = 1, P-value= 0.002). This association is also found in previous studies 
(Markos, Worku, & Davey, 2008; Cauldbeck, et al., 2009). The possibility that 
gastro-intestinal side effects, such as nausea, vomiting, abdominal discomfort as well 
as pain, and diarrhea, influence poor adherence is because these symptoms are the 
most common after patients take their ARVs and that can influence their daily 
routine. The gastro-intestinal side effects including nausea, vomiting, and abdominal 
pain are mainly caused by Nucleoside Reverse Transcriptase Inhibitors (NRTIs) such 
as AZT and D4T and diarrhea is due to Protease Inhibitors (PIs) such as KALETRA 
(Sihanouk Hospital Center of HOPE, 2008). 
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4.2.2.2. ART Regimens may influence adherence to ART 
At Sihanouk Hospital Center of HOPE (SHCH) and in Cambodia, there are 
only two ART line regimens, first line and second-line ART regimens. First-line ART 
regimen consists of seven regimens such as 3TC+EFV+AZT, 3TC+EFV+TDF, 
3TC+NVP+AZT, 3TC+NVP+TDF, ABC+3TC+EFV, D4T+3TC+EFV, and 
D4T+3TC+NVP, while second-line ART regimen is composed of four regimens such 
as 3TC+TDF+KALETRA, 3TC+TDF+KALETRA+AZT, ABC+DDI+KALETRA, 
and D4T+3TC+KALETRA. The majority 106 (90.6%) of the total 117 patients are on 
first-line ART regimens, while 11 (9.4%) patients are on second-line ART regimens. 
Among 106 patients, who are on first-line ART, 55 and 51 patients belong to poor 
adherent and good adherent patient groups, respectively. As for 11 patients, who are 
on second-line ART, five and six patients belong to poor adherent and good adherent 
patients, respectively. The number of poor ART adherent and good ART adherent 
patients on first-line ART was almost the same. Similarly, the number of poor ART 
adherent and good ART adherent patients on second-line ART was almost the same. 
Results show that both first-line and second-line ART regimens were not statistically 
significantly associated with adherence status (poor and good adherence) (X²= 0.165, 
df = 1, P-value= 0.685). This may be because almost all patients were on first-line 
ART, which has fewer pills than second-line ART or the number of poor ART 
adherent and good ART adherent is nearly the same or patients were well trained and 
educated about antiretroviral therapy or the way that patients take medications in their 
daily routine. Another possible explanation could be that both first-line ART 
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regimens and second-line ART regimens had worse side effects as just mentioned 
above. Previous studies have found similar results in favor of the results of this study 
(Markos, Worku, & Davey, 2008; Cauldbeck et al., 2009). However, Nemes, 
Carvalho and Souza (2004) and Wanjohi (2009) found that ART regimens were 
statistically significantly associated with adherence to antiretroviral therapy. 
4.2.2.3. Co-opportunistic infection treatment drugs may influence adherence to ART 
The majority 102 (87.2%) of the patients took OI drugs, while 15 (12.8%) did 
not take them. Among 102 patients who took drugs, 50 were good ART adherent 
patients, while 52 were poor ART adherent patients. Moreover, among 15 patients 
who did not take drugs, eight were poor ART adherent patients, while seven good 
ART patients. Results of this study show that co-treatments of opportunistic 
infections (OI), regardless of numbers of time (frequency) of taking drugs and 
numbers of drugs taken, were not significantly associated with adherence to 
antiretroviral therapy (X²= 0.29, df = 1, P value= 0.865). These results are consistent 
with patients’ answers to a question asked (do you have difficulty taking ARVs while 
concomitantly taking OI drugs?). 83% of 102 patients who took OI drugs said that 
they did not have difficulty taking ARVs while taking other drugs. It might be due to 
their daily routine of taking drugs, or most of the regimens were first-line ART or 
there were no drug-drug interaction, or maybe patients were aware of benefits of 
antiretroviral therapy, especially it may be due to their high commitment of taking 
drugs in order to improve their quality of life. Other previous research findings found 
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that ART regimens and co-treatment of OI drugs were not significantly associated 
with adherence to antiretroviral therapy (Markos, Worku, & Davey 2008; Zungu, 
2009; Cauldbeck et al., 2009). On the contrary, Wanjohi (2009) reported that co-
treatment of HIV and other infections were significantly associated with adherence. 
4.2.2.4. Levels of patient knowledge of ART may influence adherence to ART 
105 (89.7%) and 12 (10.3%) of the total 117 patients showed high knowledge 
and low knowledge of antiretroviral therapy, respectively. Of the 105 patients who 
had high knowledge of ART, 54 were poor ART adherent patients, while 51 good 
ART adherent patients. Among 12 patients who had low knowledge of ART, six were 
poor ART adherent patients and another six were good ART adherent patients. 
Results of analysis show that levels of patient knowledge of ART were not 
statistically significantly associated with adherence to antiretroviral therapy (X²= 
0.009, df =1, P-value= 0.925). Patients with high knowledge of ART may owe it to 
the results of hospital education and training by physicians, counselors, and also they 
can learn from their peers. However, despite high knowledge of ART, some patients 
do not perform good attitude and practice towards good adherence at all. These 
results are concordant with other previous research findings (Markos, Worku, & 
Davey, 2008; Cauldbeck et al., 2009). 
4.2.2.5. Educational levels of patients may influence adherence to ART 
Educational backgrounds of research subjects in this study were divided into 
four levels: illiterate 31 (26.5%), primary school 40 (34.2%), secondary school 27 
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(23.1%), and high school or university 19 (16.2%). It is seen in the findings chapter 
that among 117 respondents, the number of patients attending primary school is the 
highest, followed by illiterate, secondary school, and high school or university. In 
illiterate level, there were 31 patients; of these, 19 were poor adherent patients, while 
12 good adherent patients. Next, in primary school level, of the 40 patients, 22 and 18 
were poor ART adherent and good ART adherent patients, respectively. Among 27 
patients in secondary school level, 12 were poor ART adherent patients, while 15 
good ART adherent patients. Furthermore, of the 19 patients in high school or 
university level, seven were poor ART adherent patients, while 12 good ART 
adherent patients. Even though there is a difference between the numbers of poor and 
good ART adherent patients in each level of education, results of analysis show that 
there is no statistically significant association between educational levels and 
adherence to antiretroviral therapy (X²= 3.555, df= 3, P-value= 0.314). It seems likely 
that patients may have poor adherence to antiretroviral therapy when their educational 
background is low; however, high educational background seems to be a predictor of 
good adherence. In contrast, in this study education regardless of levels of study was 
not significantly associated with ART adherence. This might be because of poor 
attitude and practice. The results of this study are relevant to other research findings 
(Markos, Worku, & Davey, 2008; Cauldbeck et al., 2009). However, some previous 
research findings contrast with this study (Nemes, Carvalho & Souza, 2004; Wanjohi, 
2009). 
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4.2.2.6. Patient’s location of residence may influence adherence to ART 
73 (62.4%) of all research respondents live in Phnom Penh, while 44 (37.6%) 
live in provinces. 37 out of 73 patients who live in Phnom Penh were poor ART 
adherent patients, while 36 were good ART adherent patients. Among 44 research 
respondents who live in provinces, 23 were poor ART adherent patients, while 21 
were good ART adherent patients. Apparently, there is almost the same number of 
poor and good adherent patients living in Phnom Penh, and also the number of poor 
and good adherent patients living in provinces. Results of analysis demonstrate that 
patient’s location of residence has no significant association with adherence to 
antiretroviral therapy (X²=0.28, df =1, P-value= 0.868). This may be due to almost no 
difference between the number of poor adherent patients and good adherent patients 
in both sites. Some might think that when living far away from health facility, 
patients seem to perform poor ART adherence because of the cost and time spent on 
transportation, foods, and difficult access to health facilities. Some previous study 
findings are consistent with the results of this study (Hardon et al, 2006; Cauldbeck et 
al., 2009). On the contrary, one previous research finding found that living away from 
home was significantly associated with poor adherence (Markos, Worku, & Davey, 
2008). 
4.2.2.7. Poverty status of patients may influence adherence to ART 
82 (70.1%) of the 117 research subjects were poor, while 35 (29.9%) were not 
poor. However, there was almost no difference between the number of poor ART 
adherent patients (42) and good ART adherent patients among all poor patients (40). 
136 
 
Similarly, of the 35 patients who were not poor, 18 were poor ART adherent patients, 
while 17 are good ART adherent patients. There is no statistically significant 
association between poverty status and adherence to antiretroviral therapy (X²=0.000, 
df =1, P value=0.983). This might be due to almost the same numbers of poor ART 
adherent patients and good ART adherent patients in poor and not poor patients’ 
groups or it seems that poor patients might have high commitment to take ARVs in 
order to improve their quality of life because they cannot afford to buy drugs by 
themselves. This finding is consistent with other previous findings (Orrell, 
Bangsberga, Badri, & Wood, 2003; Cauldbeck et al., 2009). In contrast, some 
previous studies found that poverty is statistically significantly associated with poor 
ART adherence (Nemes, Carvalho & Souza, 2004; Machtinger & Bangsberg, 2006; 
Wanjohi, 2009). 
4.2.3. Results of socio-demographic and economic factors 
There are seven socio-demographic and economic factors: gender, age groups, 
CD4 groups, WHO stages, marital status, occupations, and food access status. 
4.2.3.1. Gender  
45 (38.5%) of all research respondents were males, while 72 (61.5%) were 
females. Among 45 male patients, 26 were poor ART adherent patients, while 19 are 
good ART adherent patients. 34 of 72 female patients were poor ART adherent 
patiernts, while 38 were good ART adherent patients. Results of the analysis show 
that there is no statitistically significant association between gender and adherence to 
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antiretroviral therapy (X²= 1.235, df = 1, P-value=0.266). This result is supported by 
previous research findings (Orrell, Bangsberga, Badri, & Wood, 2003, Erah, & Arute, 
2008). However, some previous study findings showed that gender is associated with 
ART adherence (Shernoff, 2001; Kennedy, Goggin, & Nollen, 2004; Cauldbeck et 
al., 2009). 
4.2.3.2. Age groups 
As mentioned in chapter III, age groups are classified into five categories. 
Age groups 30-34 and 35-39 years had greater numbers than those in other age 
groups. These two groups account for 23.1 and 23.9%, respectively. Results of 
analysis reveal that age groups were not associated with ART adherence (X²= 2.315, 
df= 4, P-value= 0.678). This result is consistent with previous research findings 
(Nemes, Carvalho & Souza, 2004; Erah & Arute, 2008). On the contrary, other 
previous research findings revealed that age groups were associated with ART 
adherence (Nemes, Carvalho & Souza, 2004; Machtinger & Bangsberg, 2006; 
Wanjohi, 2009; Cauldbeck et al., 2009). 
4.2.3.3. CD4 groups 
As seen in the findings chapter, CD4 groups were divided into three 
categories. Of these, CD4 group 1-99 accounted for the majority (56.4%). However, 
of all patients (66) in this CD4 group, the numbers of poor and good ART adherent 
patients are the same (33). Similarly, the numbers of poor ART adherent patients and 
good ART adherent patients in the other two CD4 groups are almost the same. 
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Results of analysis indicate that CD4 groups were not statistically significantly 
associated with adherence to antiretroviral therapy. ART adherence might be 
influenced by other factors, for example, ART side effects, other than CD4. Other 
findings are in favor of this result (Erah & Arute, 2008; Ford, Darder, Spelman, 
Maclean, Mills, & Boulle, 2010). In contrast, previous research findings 
demonstrated that CD4 is statistically significantly associated with ART adherence 
(Wood, Hogg, Yip, Harrigan, O’Shaughnessy, & Montaner, 2003; Machtinger & 
Bangsberg, 2006). 
4.2.3.4. WHO stages 
Among all the research respondents, WHO stage 3 and WHO stage 4 accounts 
for 44.4% and 35%, respectively. While the other stages represent the minority. 
Among seven respondents in WHO stage 1, six are poor ART adherent patients, 
while one is good ART adherent patient. However, the numbers of poor ART 
adherent and good ART adherent patients in WHO stage 2 are almost the same, nine 
and eight, respectively. Among 52 respondents in WHO stage 3, 24 are poor ART 
adherent patients, while 28 are good ART adherent patients. This shows a slight 
difference between the numbers of poor and good ART adherent patients. However, 
of all 41 respondents in WHO stage 4, the numbers of poor and good ART adherent 
patients were almost the same, 21 and 20, respectively. Results of analysis show that 
WHO stages were not significantly associated with ART adherence (X²= 3.888, df= 
3, P-value= 0.274). ART might be influenced by other factors such complex ART 
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regimens, socio-demographic characteristics, and disease factors. This result is 
consistent with some previous research findings (Orrell, Bangsberga, Badri, & Wood, 
2003; Bajunirwe, Arts, Tisch, King, Debanne, & Sethi, 2009). However, it is in 
contrast with previous research findings (Wood, Hogg, Yip, Harrigan, 
O’Shaughnessy, & Montaner, 2003; Cauldbeck et al., 2009). 
4.2.3.5. Marital status 
As shown in findings chapter, the majority (59%) of the respondents were 
married, followed by divorced (20.5%). The remaining marital status categories 
represent the minority. Among 69 married respondents, 37 were poor ART adherent 
patients, while 32 were good ART adherent patients. Of the 24 divorced respondents, 
13 were poor ART adherent patients, while 11 were good ART adherent patients. 
Results of analysis demonstrate that marital status was not statistically significantly 
associated with adherence to antiretroviral therapy (X²= 5.289, df= 5, P-value = 
0.382). This result is compatible with previous research findings (Orrell, Bangsberga, 
Badri, & Wood, 2003; Huong, 2009; Bajunirwe, Arts, Tisch, King, Debanne, & Sethi, 
2009). However, this result is not consistent with some other previous research 
findings (Nemes, Carvalho, & Souza, 2004; Machtinger & Bangsberg, 2006; 
Wanjohi, 2009). 
4.2.3.6. Occupations 
As described in findings chapter, the numbers of respondents who had a small 
business, were unemployed, and company workers accounted for 31 (26.5%), 27 
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(23.1%), 25 (21.4%), respectively. While the other occupation categories represent 
the minority. 16 of 31 respondents, who had small business or were self-employed, 
were poor ART adherent patients, while 15 were good ART adherent patients. 
Among 27 unemployed, 12 were poor ART adherent patients, while 15 were good 
ART adherent patients. 17 out of 25 company workers were poor ART adherent 
patients, while eight were good ART adherent patients. Results of analysis show that 
occupations were not significantly associated with ART adherence. Previous research 
findings are in favor of this result (Orrell, Bangsberga, Badri, & Wood, 2003; 
Markos, Worku, & Davey, 2008). However, findings of some previous studies are 
against this result (Nemes, Carvalho, & Souza, 2004; Machtinger & Bangsberg, 2006; 
Wanjohi, 2009; Huong, 2009). 
4.2.3.7. Food access status 
68 (58.1%) and 49 (49.1%) of all research respondents have enough and do 
not have enough food to eat every day, respectively. 36 out of 68 respondents who 
had enough food to eat were poor ART adherent patients, while 32 were good ART 
adherent patients. Among 49 respondents who did not have enough food to eat every 
day, 24 were poor ART adherent patients, while 25 were good ART adherent 
patients. Although about 49 percent of all the patients who participated in the study 
did not have enough food to eat every day, this number is higher than poverty rate in 
Cambodia, which is about 35 percent of the total population. Results of analysis in 
this study demonstrate that food access was not statistically significantly associated 
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with adherence to antiretroviral therapy (X²= 0.179, df = 1, P-value= 0.672). This 
result is in agreement with one previous research finding (Manary, Ndekha, & 
Oosterhout, 2010). However, this result is consistent with previous research findings 
(Nemes, Carvalho, & Souza, 2004; Machtinger & Bangsberg, 2006; Huong, 2009; 
Wanjohi, 2009). 
4.3. Conclusions 
Cambodia is one of the developing countries that have been hit by HIV/AIDS 
epidemic and many AIDS patients have died of this disease. In order to contain the 
epidemic and reduce the morbidity and mortality related to HIV/AIDS, the Royal 
Government of Cambodia, along with civil societies, local and international 
organizations, and other stakeholders, has co-operated and worked together to prevent 
HIV transmission, provide patients with care, treatment, support, and other related 
managements. Moreover, antiretroviral therapy coverage has been expanded and 
increased rapidly in order to meet the demands of HIV/AIDS patients. ART program 
in Cambodia has been successful and has reduced HIV prevalence, morbidity and 
mortality and burdens related to the disease dramatically. Also, the effectiveness of 
ART program has improved the quality of life of HIV/AIDS patients substantially. 
Because the number of people living with HIV/AIDS needing ART has increased 
rapidly, appropriate measures need to be taken thoroughly and carefully in order to 
achieve long-term success. Adherence to antiretroviral therapy is one of the key 
factors that contribute to the effectiveness and success of antiretroviral therapy and it 
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needs to be optimal, otherwise the success of treatment cannot be achieved. 
Adherence to ART faces many problems; however, there has been so far nearly no 
study on problems that can lead to poor ART adherence in Cambodia. Hence, the 
author chose to study barriers to antiretroviral therapy adherence of HIV/AIDS 
patients at Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia. 
The findings of the study show that the majority of all research respondents 
(93%) were good ART adherent patients, whereas seven percent were poor ART 
adherent patients. The main factors for good ART adherence cited by research 
respondents are access to alarm clock, reminders of family, relatives, and friends, as 
well as high commitment of patients. The reasons for poor ART adherence also 
reported by research respondents are forgetfulness, being busy, lack of time 
reminders, seriousness of diseases, stigma/discrimination, ART side effects, and high 
pill burdens. Univariate data analysis shows that ART side effects are the only one 
factor of the other hypotheses that is statistically significantly associated with poor 
ART adherence (X²=7.150, df =1, P-value =0.007). Exclusively, of all ART side 
effects, gastro-intestinal symptoms were the only one factor that is statistically 
significantly associated with poor ART adherence (X²= 9.535, df= 1, P-value= 
0.002). The other hypotheses such as ART regimens, co-opportunistic infection drug 
treatments, knowledge of ART, educational levels, patient’s location of residence, 
and poverty status are not significantly associated with poor ART adherence. Other 
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factors such as gender, age groups, CD4 groups, WHO stages, marital status, 
occupations, and food status are not significant predictors for poor ART adherence.  
Therefore, the significant barriers to adherence to antiretroviral therapy 
adherence of the HIV/AIDS patients at Sihanouk Hospital Center of HOPE are side 
effects of antiretroviral treatments. Other factors such as forgetfulness, being busy, 
lack of time reminders, seriousness of disease, social and cultural factors such as 
stigma and discrimination are also predictors of poor adherence to antiretroviral 
therapy. 
4.4. Policy implications  
Based on discussions and conclusions above, levels of adherence to 
antiretroviral therapy of HIV/AIDS patients at Sihanouk Hospital Center of HOPE 
and in Cambodia are generally good; however, poor ART adherence still exists and 
needs to be addressed by stakeholders including people who are responsible for ART 
program and those working for relevant governmental and non-governmental 
institutions. Therefore, in order to improve adherence to antiretroviral therapy of 
HIV/AIDS patients in Cambodia, the implication of comprehensive interventions is 
needed and some recommendations can be considered and made as follows: 
 ART programs should provide clinicians with more education and training 
on antiretroviral therapy and management of ART side effects. The 
programs could also train counselors to educate and counsel HIV/AIDS 
patients to improve their ART adherence during hospital visits and other 
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activities. Doctors should closely observe and manage ART side effects 
including nausea, vomiting, abdominal pain, and diarrhea. In case that the 
adverse effects are worsening or remains permanent, they may change the 
most likely drugs. 
 Physicians, nurses, pharmacists, counselors, and home-based care workers 
need to work as a team in order to achieve a common goal of ART 
success. For that reason, they need to educate and train HIV/AIDS patients 
to understand the benefits and goal of antiretroviral therapy appropriately. 
Most importantly, physicians should explain deeply, thoroughly, and well 
in advance to patients that ART side effects may occur after they take 
antiretroviral drugs. Moreover, doctors should educate and train 
HIV/AIDS patients to understand and recognize adverse effects of ART 
and ask the patients to inform them in case that ART side effects happen 
or doctors should tell patients to go to hospital for side effect management. 
 The Ministry of Health of Cambodia could improve and strengthen quality 
of HIV/AIDS disease treatment and management, especially ART side 
effects of clinicians, nurses, pharmacists, and counselors who are working 
in ART sites in the country as a whole. Moreover, the Ministry of Health 
could consider policy on program switching ARV drugs that are most 
likely to cause side effects such as nausea, vomiting, abdominal pain, and 
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diarrhea or if possible, the Ministry of Health could provide alternatives of 
ARV drugs that can avoid gastro-intestinal adverse effects. 
 The Royal government of Cambodia through the Ministry of Health, 
authority/community, civil society, non-governmental organizations 
(NGO), and other involved ministries should work together so as to 
intensify health education campaigns against stigma and discrimination, 
provide more job opportunity, promote family and community support for 
HIV/AIDS patients, and to provide patients with time reminders such as 
alarm clock.  
The findings of this study would be important for ART program managers and 
policy makers to improve the success of antiretroviral therapy. Thus, the Cambodian 
government can have the best opportunity to save more money and contribute to 
country development. 
4.5. Suggestion for future research 
 Studies on a bigger sample and using mixed methods including subjective 
self-report and objective pill count to assess adherence to antiretroviral 
therapy of people living with HIV/AIDS should be conducted.  
 Studies on ART adherence should focus on both HIV/AIDS patients and 
health care providers in order to produce more reliable and accurate 
results. 
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 Studies should be conducted in more than one setting and need to be 
compared with other settings in urban and rural areas. 
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APPENDICES 
Appendix 1: Consent form 
My name is HING Kim. I am a Master of Public Health Management student 
at the Ritsumeikan Asia Pacific University, Japan. I am conducting a survey on 
‟Barriers to Antiretroviral Therapy Adherence of HIV/AIDS Patients at Sihanouk 
Hospital Center of HOPE.‖ This survey is conducted to fulfill two purposes: 
completion of my Master Degree and contribution to antiretroviral therapy program 
in Cambodia. The information you give to me is very important and therefore kindly 
be sincere in your responses. I assure you that the information that you provide to me 
will be handled with total confidence and nobody will identify your name. Your name 
will not be written on the questionnaire or kept in any other records. Your 
participation is voluntary and you can decide to stop the interview at any time. 
 
 
Signature…………………………………….Date……………………………
……… 
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Appendix 2: Questionnaire for interview 
 (A) Basic Information 
 Date of interview.   
 Study site.    
 Code of the interview …………………………… 
WHO stage of respondent……………………….. 
 (B) Socio-Demographic Information 
1. Sex of participant:  (1) Male [ ]   (2) Female [ ] 
2. How old are you?................................................... 
3. What is your marital status? 
1). Single [ ] 
2) Married [ ] 
3). Separated  [ ] 
4) Divorced [ ] 
5) Widowed [ ] 
6) Widower [ ] 
7) Co-habiting (not married but living with partner) [ ] 
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4. Where do you live? 
1) Phnom Penh [ ] 
2) Province [ ] 
 (C) Socio-Economic Information 
5. What is your education background? 
 1) Illiterate [ ] 
 2) Primary school [ ] 
 3) Secondary school [ ] 
 4) High school [ ] 
 5) University [ ] 
6. What is your occupation? 
1) Unemployed [ ] 
2) Farmer [ ] 
3) Civil servant [ ] 
4) Small business/self-employed [ ] 
5) Company worker [ ] 
6) NGOs staff [ ] 
7) Others (specify)…………………………………….. 
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7. How much money do you earn per day? 
………………………………………………………. 
8. How much do you spend per day?      
………………………………………………………. 
9. Do have enough food to eat every day? 
 1) Yes  [ ] 
 2) No  [ ]          
 (D) Knowledge of ART Drugs 
10. Why do you take ARV drugs? 
1) To cure HIV/AIDS [ ] 
2) Not for curing HIV/AIDS but to prolong life [ ] 
3) Reducing pain [ ] 
4) Stop progression of HIV/AIDS [ ] 
5) I don’t know [ ] 
6) Others …………………………………………………………… 
11. How many ARV drugs need to be taken together for effective treatment? 
 1) Do not know [ ] 
2) One ARV drug [ ] 
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 3) Two ARV drugs [ ] 
 4) Three ARV drugs [ ] 
 5) Others [ ] 
12. How long is the ARV treatment? 
 1) Do not know [ ] 
 2) One month [ ] 
 3) Two months [ ] 
 4) Six months [ ] 
 5) Lifelong [ ] 
 6) Others ………………………………………………………….. 
13. What are the side effects that may happen during ART?  
1) Skin rash [ ] 
2) Gastro intestinal problem (Vomiting and abdominal pain…) [ ] 
3) Night mare [ ] 
4) Liver toxicity ( jaundice on eyes and skin) [ ] 
5) Anemia [ ] 
6) Lipodystrophy [ ] 
7) Others ………………………………………………………… 
14. What will you do if side effects happen? 
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 1) Stop taking ARV by myself [ ] 
 2) Buy drug from pharmacy to treat side effect [ ] 
 3) Call doctor for advice [ ] 
 4) Go to hospital for consulting with doctor [ ] 
 5) Do not know [ ] 
 6) Others ………………………………………………………….. 
15. What are the benefits of taking ARV regularly, correctly and continuously?  
1) Suppression of HIV viral load in blood [ ] 
2) Avoidance of resistance of HIV to ARV [ ] 
3) Achievement of ART success [ ] 
4) Do not know [ ] 
5) Others (specify………………….) 
 (E)Treatment Regimen  
16. Which ART drugs are you currently taking? 
Abacavbir (ABC) 1) Yes 2) No 
Didanosine (DDI) 1) Yes 2) No 
Stavudine (D4T) 1) Yes 2) No 
Lamivudine (3TC) 1) Yes 2) No 
Efavirenz (EFZ) 1) Yes 2) No 
Nevirapine (NVP) 1) Yes 2) No 
Tenofovir (TDF) 1) Yes 2) No 
Lopinavir/ritonavir (KALETRA) 1) Yes 2) No 
Zidovudine (AZT) 1) Yes 2) No 
Others (specify) 1) Yes 2) No 
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17. What other drugs (besides anti-retroviral) are you currently on (tick as 
appropriate) 
Tick Drug and How many times per day 
 
Tick Drug How many times per day 
1 Appetitive stimulants/vitamins  
2 Antibiotics (other than TB)  
3 Co-trimoxazole prophylaxis  
4 Fluconazole prophylaxis  
5 Fungal infection treatment  
6 Pain killers  
7 Sleeping pills  
8 TB drugs  
9 
Others 
(specify………………………) 
 
18. Do you have difficulty taking ARVs while using drugs in question 17? 
1) Yes  [ ] 
(why?.................................................................................) 
2) No  [ ] 
(why……………………………………………………..) 
 (F) ART Side Effects  
19. Did you experience drug side effects? If your answer is No, please skip the 
question 20 and 21, and then go on to question 22.  
1) Yes [ ] 
2) No [ ] 
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20. What are the side effects that you experienced?  
1) Skin rash [ ] 
2) Gastro intestinal problem (Vomiting and abdominal pain…) [ ] 
3) Night mare [ ] 
4) Liver toxicity ( jaundice on eyes and skin) [ ] 
5) Anemia [ ] 
6) Lipodystrophy [ ] 
7) Others (specify……………………………………) 
21. Did side effects cause you to stop taking the medicines?  
1) Yes [ ] 
2) No [ ] 
 (G) Characteristics of ART Adherence and Reasons Reported for Missing ART 
Doses 
22. Did you take ARVs regularly and correctly? If your answer is Yes, please go on 
to question 23 and then finish interview ; if your answer is No, please skip 
question 23 and go on to question 24. 
1) Yes [ ] 
2) No  [ ],  
23. What are the factors that help you take ARVs regularly, continuously, and 
correctly?........................................ 
24. What causes you not to take your tablets? 
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1) Developed toxicity/ side effect [ ] 
2) Forgot to take ART [ ] 
3) Felt better [ ] 
4) Too ill [ ] 
5) Fear of stigma/disclosure [ ] 
6) Stock was finished [ ] 
7) Drunk with alcohol [ ] 
8) Too many pills/ pill burden [ ] 
9) Other 
(specify)__________________________________________________. 
25. Many people find it hard to remember to take every single dose; in the last one 
month, how many doses have you missed? 
Name of drug Number of doses missed 
  
  
  
  
  
 
Thank you for taking time to participate in this interview 
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Appendix 3: Recommendation letter from APU to Sihanouk Hospital Center of 
HOPE 
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Appendix 4: Recommendation letter from APU to National Ethics Committee 
for Health Research of Cambodia 
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Appendix 5: Permission letter from Sihanouk Hospital Center of HOPE 
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Appendix 6: Permission letter of National Ethics Committee for Health Research 
of Cambodia for conducting field research 
 
